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ABSTRACT 
Despite extensive research, the mechanisms behind cardiovascular effects of subchronic 
environmental tobacco smoke (ETS) remain unclear, but may be related to ETS-induced 
inflammation and oxidative stress. Additionally, the protective role of resveratrol (RES), a 
natural antioxidant available in red grapes, is controversial. We hypothesized that the polycyclic 
aromatic hydrocarbon (PAH) component of ETS is responsible for causing adverse 
cardiovascular effects. We also hypothesized that the administration of RES is protective 
against the adverse cardiovascular effects of ETS. In order to address these hypotheses, male 
juvenile pigs (4-weeks old) were exposed to ETS or ambient air for 28 consecutive days (1 
hr/day) and effects compared to 7 days of i.v. injection of the PAH, benzo-a-pyrene (BAP; 5 
mg/kg daily). In another experiment, pigs were sham-exposed or ETS-exposed, with or without 
oral RES treatment (5mg/kg daily). In all experiments, endothelial and left ventricular function 
were assessed by flow mediated dilation (FMD), and echocardiography, respectively, while 
blood pressure was evaluated by oscillometry. At the termination of each experiment, serum 
nitrotyrosine, total nitrate/nitrite (NOx) and C-reactive protein (CRP) were measured as well as 
hepatic and pulmonary ethoxyresorufin-o-deethylase (EROD) activity to indicate cytochrome 
P450 1A1 (CYP1A1) expression. Finally, the correlation between pulmonary inflammation and 
adverse cardiovascular effects was investigated by measuring total and differential white blood 
cell (WBC) count as well as leukocyte elastase activity in bronchoalveolar lavage fluid at the 
termination of each experiment. ETS exposure, but not BAP treatment, resulted in a significant 
impairment of FMD (P<0.0001) and increased left ventricular end diastolic volume (P=0.0032). 
Cotreatment with RES failed to restore the ETS induced impairment of FMD (P>0.05). 
However, a trend pointing to an increase in ejection fraction (EF) was noted (P=0.072).  ETS, 
BAP and RES treatments failed to have any effect on blood pressure (P>0.05). BAP injection 
caused a significant increase in serum nitrotyrosine (P=0.0146) and CRP (P=0.012), but not 
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serum NOx levels (P>0.05). In contrast, ETS exposure resulted in a significant increase in CRP 
serum levels (P=0.0092), a trend pointing to increased serum nitrotyrosine (P=0.105), and no 
change in serum NOx levels (P>0.05). The increased nitrotyrosine and CRP with ETS exposure 
was not reversed by RES administration (P>0.05).  ETS exposure increased EROD activity in 
the lung (P=0.0093), but not the liver (P=0.12). In contrast, BAP treatment had the opposite 
effect (lung EROD: P=0.621, liver EROD: P=0.01), while RES administration had no effect 
(P>0.05). ETS exposure (P=0.0139), but not BAP treatment (P=0.723), resulted in increased 
WBC count in BAL fluid which was not affected by RES administration (P>0.05). These results 
show that ETS exposure causes lung inflammation, systemic inflammation, oxidative stress-
mediated inactivation of nitric oxide and impaired endothelial function. In contrast, BAP failed 
to alter endothelial function, downstream of the lung, despite systemic inflammation and 
increased oxidative stress. Furthermore, RES failed to restore endothelial function, or decrease 
systemic inflammation and oxidative stress. Taken together, these results suggest either that 
pulmonary inflammatory responses or pulmonary increases in CYP1A1 activity may be more 
important links to endothelial dysfunction than systemic inflammation and nitric oxide 
bioactivity. The beneficial effects of RES by itself are manifested only at the cardiac level by 
improving the ejection fraction, but the work in this thesis failed to detect any ability of RES to 
ameliorate ETS cardiovascular effects. 
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1. Introduction 
This study aimed to determine the impact of a long term exposure to environmental 
tobacco smoke (ETS) on the cardiovascular and pulmonary systems utilizing a swine model. 
Another goal was to determine the role of polycyclic aromatic hydrocarbons (PAHs) in 
mediating these effects through the intravenous injection of a specific ETS constituent i.e. 
benzo[a]pyrene (BAP). The same suite of cardiovascular, pulmonary, biochemical and 
histological parameters was measured in both studies.  
The experimental work in this thesis is divided into two sections, each written in a 
manuscript format ready for publication. The first manuscript deals with the effects of ETS 
and BAP on the cardiovascular system, and the second examines the cardiovascular 
protective role of resveratrol (RES) when co-administered with ETS exposure.  The thesis is 
divided into 7 chapters with the first one being this introduction. Chapter 2 is the literature 
review, where most recent studies about this topic are cited. Chapter 3 contains the 
hypotheses and objectives of this thesis. This is followed by chapter 4, containing the first 
manuscript of this thesis. Chapter 5 contains the 2
nd
 manuscript of this thesis. Chapter 6 
contains the overall discussion and conclusion of this thesis. Finally, chapter 7 lists all the 
references cited in this thesis.  
 
 
 
 2 
  
2
 
2. Literature review 
2.1. Cardiovascular disease (CVD) statistics and risk factors 
The term cardiovascular disease (CVD) refers to a number of different disease processes 
that involve the heart and vasculature, including coronary heart disease, peripheral artery 
disease and stroke. Cardiovascular disease remains a major cause of death in North America 
and worldwide. In the United States 2300 Americans
 
die of CVD on a daily basis with 
coronary heart disease responsible for 1 in every 6 deaths in 2006 (Lloyd-Jones et al.). In 
Canada it is estimated that 1 person dies from heart disease or stroke every 7 minutes. In 
2006, CVD accounted for 30% of deaths in Canada (Statistics Canada, 2010).  
Several risk factors have been identified for CVD some of which are modifiable while 
others are not. Among the modifiable risk factors smoking, obesity, decreased activity, high 
blood cholesterol and glucose, and high blood pressure are most important. Non-modifiable 
risk factors include genetics, aging and male gender (O'Donnell and Kannel, 1998). 
 
2.2. Cardiovascular disease mechanisms 
2.2.1.Atherosclerosis 
The main pathophysiological process involved in the development of CVD is 
atherosclerosis (Kumar V, 2010). Atherosclerosis is a disease affecting medium and large 
sized arteries characterized by the presence of subintimal thickening known as atheromatous 
plaques. These arterial plaques are composed of a central core of lipid infiltrated by 
macrophages and surrounded by a fibrous cap. Atheromatous plaques not only interfere with 
blood flow but can also result in vascular thrombosis and aneurysm (Crowther, 2005). 
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 Two major theories have been proposed to explain the development of atherosclerosis. 
The first theory is known as the response to injury hypothesis. According to this theory, the 
initial event in atherosclerosis development is endothelial injury. Endothelial injury is 
followed by modulation of growth factors and cytokine production resulting in uncontrolled 
smooth muscle proliferation (Ross and Glomset, 1973). In contrast, Benditt explained the 
development of atherosclerotic lesions as benign neoplasms arising from smooth muscles 
within the vasculature (Benditt and Benditt, 1973). The earliest lesion seen in atherosclerosis 
is known as fatty streak which is composed of lipid laden macrophages within the 
subendothelial space. This is followed by the migration of smooth muscles from tunica media 
into the subintimal space and extracellular matrix production to form the atheromatous 
plaque. The major mechanisms involved in atherosclerosis include endothelial dysfunction, 
hemodynamic disturbances, hyperlipidemia and hyperglycemia, and infection (Kumar V, 
2010). 
 
2.2.2.Normal endothelial function  
Endothelial cells play a key role in the regulation of vascular tone as well as coagulation 
and inflammation, all of which are implicated in the development of atherosclerosis. The 
endothelium is responsible for the regulation of cardiovascular tone by generating active 
mediators including nitric oxide (NO), endothelium-derived relaxing factor, and endothelin 
(Bellien et al., 2008; Busse and Fleming, 2006; Luscher, 1994). Normally, increased arterial 
shear stress results in increased intracellular calcium within endothelial cells (Busse and 
Fleming, 2006). As a result, an enzyme known as endothelial NO synthase (eNOS) is 
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activated and NO is generated (Busse and Fleming, 2006). After diffusing into smooth 
muscles, NO activates the enzyme guanylate cyclase which increases the production of cyclic 
guanosine monophosphate (cGMP). cGMP activates cGMP-dependent protein kinase which 
mediates vascular smooth muscle relaxation and ultimately results in vasorelaxation (Munzel 
et al., 2005). Vascular smooth muscles are also capable of proliferation, migration and 
extracellular matrix deposition. Such functions are physiologically regulated by growth 
promoters and inhibitors (Rzucidlo, 2009). Promoters include platelet derived growth factor, 
produced by platelets, endothelial cells, and macrophages, basic fibroblast growth factor, and 
interleukin-1 (IL-1). Inhibitors include NO and transforming growth factor- β (Rzucidlo, 
2009).  
By modulating the expression of adhesion molecules on its surface the endothelium plays 
a role in regulating inflammation (Galkina and Ley, 2007). For example, the endothelium 
expresses intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule 
(VCAM-1) both of which are essential for macrophage migration in atherosclerosis. 
Intercellular adhesion molecule-1 knockout mice are protected from atherosclerosis (Collins 
et al., 2000) and mice with reduced VCAM-1 expression have reduced atherosclerotic lesions 
(Dansky et al., 2001).  Nitric oxide also regulates several other processes including platelet 
activation and coagulation (Radomski et al., 1990). Therefore, the impairment of NO 
production is involved in the progression of atherosclerosis.  
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2.2.3.Endothelial dysfunction 
Endothelial dysfunction represents an important early step in the pathogenesis of 
atherosclerosis. Endothelial dysfunction is characterized by endothelial cells becoming 
proinflammatory and prothrombotic with reduced vasodilator function (Endemann and 
Schiffrin, 2004). Several disease processes and toxins may contribute to the development of 
atherosclerosis by causing endothelial dysfunction. Examples include hypertension, 
hypercholesterolemia, cigarette smoking, and diabetes (Kumar V, 2010). Endothelial injury 
is usually associated with increased oxidative stress (Schulz et al., 2008). The interaction of 
reactive oxygen species (ROS), such as superoxide anion, with NO, produced by endothelial 
cells, results in the formation of peroxynitrite (Schulz et al., 2008). Peroxynitirite can impair 
vasodilatation by inactivating the enzymes eNOS and prostacyclin synthase (Zou et al., 
2002a; Zou and Ullrich, 1996). Peroxynitrite is highly reactive, short lived and forms 
nitrotyrosine after it interacts with tyrosine residues in proteins. Not only can peroxynitrite 
uncouple the enzyme eNOS, but it also can turn it into a source of free radicals (Zou et al., 
2002b). When uncoupled, eNOS generates superoxide anions by transferring electrons to 
molecular oxygen instead of L-arginine (Munzel et al., 2005; Schulz et al., 2008). The net 
result is decreased eNOS activity, decreased NO production, decreased NO bioavailability 
and increased oxidative stress. Underlying mechanisms for eNOS uncoupling include the 
depletion of tetrahydrobiopterin (BH4), a cofactor for eNOS production, and L-arginine, the 
substrate for NO (Mehta et al., 2006). 
Ultimately, endothelial injury causes subintimal lipid accumulation and increased 
expression of adhesion molecules on the surface of endothelial cells. In humans, brachial 
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artery flow-mediated dilation, measured using high resolution ultrasound, is a noninvasive 
and broadly
 
applicable method used to evaluate endothelial function (Martin, 2009). 
 
2.2.4.Roles of elevated blood lipids and glucose 
Cholesterol and fatty acids are transported in the circulation by many plasma 
lipoproteins. Low density lipoprotein (LDL) is the principal plasma cholesterol carrier 
(Crowther, 2005). Low density lipoprotein is recognized and internalized by the LDL 
receptor (LDLR), which is ubiquitously expressed (Miller et al., 2010). In situations with 
increased oxidative stress LDL is modified to an oxidized form i.e. oxLDL (Li and Mehta, 
2005). Endothelial cells internalize oxLDL through LOX-1 receptors (Sawamura et al., 
1997).  Additionally, LDL can be modified by enzymes and free radicals within the 
subintimal space to form oxLDL. Then oxLDL is taken up by macrophages which in turn 
become foam cells (Lucas and Greaves, 2001).  OxLDL can also result in the increased 
expression of monocyte chemotactic protein-1 (MCP-1), and macrophage colony stimulating 
factor (MCSF), thereby promoting monocyte recruitment (Osterud and Bjorklid, 2003). 
Oxidized LDL can also uncouple eNOS and result in decreased NO bioavailability (Li and 
Mehta, 2005). 
Additionally the long standing hyperglycemia and hyperinsulinemia along with the 
production of advanced glycation end products seen in diabetes, results in increased 
production of endothelin-1. Endothelin-1 not only increases vascular tone, but also activates 
the rennin-angiotensin system and promotes inflammation and smooth muscle proliferation 
(Creager et al., 2003).  
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2.2.5.Oxidative stress and inflammation  
C-reactive protein (CRP) is an acute phase protein elevated during systemic inflammation 
(Antoniades et al., 2004). C-reactive protein is produced by the liver and its synthesis is 
stimulated by interleukin-6 (IL-6) secreted by macrophages (Whiteley et al., 2009). 
Individuals with high CRP and IL-6 serum levels are at increased risk of developing CVD 
(May and Wang, 2007). The role of oxidative stress and inflammation in the progression of 
atherosclerosis cannot be over-emphasized. Atherosclerosis and its risk factors, including 
diabetes and hypercholesterolemia, are usually associated with low grade inflammation 
(Duncan et al., 2003) which may in turn lead to the increased production of ROS within the 
vasculature (Libby, 2002; Packard and Libby, 2008). Free radicals can be cytotoxic and may 
cause damage to DNA, proteins, and lipids (Beckman and Koppenol, 1996). Despite the early 
observation that macrophages within atherosclerotic lesions give rise to foam cells containing 
cholesterol (Osterud and Bjorklid, 2003), the role of LDL in atherosclerosis was always 
questioned as LDL, by itself, did not appear to be atherogenic. Macrophages, reportedly, 
failed to internalize excess lipoprotein-cholesterol in vitro as LDL receptor is down regulated 
(Goldstein and Brown, 1977). It is now recognized that the oxidation of lipoprotein results in 
its conversion into a high uptake lipid form i.e. oxLDL (Vogiatzi et al., 2009).  This leads to 
endothelial dysfunction, smooth muscle de-differentiation and foam cell formation (Vogiatzi 
et al., 2009). Peroxynitrite can also inactivate prostacyclin synthase, leading to decreased 
prostacyclin production and impaired vasodilatation (Zou et al., 1999). A major source of 
super oxide anion is the enzyme nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase, a complex enzyme with cytoplasmic and membrane components abundant in 
macrophages (Lassegue and Clempus, 2003). It has been found that many vascular cell types 
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express several components of the NADPH oxidase enzyme with oxidase activity, and may 
therefore contribute to oxidative injury (Yokoyama and Inoue, 2004).  
 
2.3. Cigarette smoking 
2.3.1.History of tobacco use 
Tobacco leaves or Nicotiana tabacum were grown in Cuba and on several of the West 
Indies Isles, as well as the east coast of North America from Florida to Virginia for centuries. 
It was the Spanish and Portuguese merchants who first took tobacco plant seeds to Europe. In 
fact, the tobacco plant was named “Nicotina” after the French ambassador to Portugal Jean 
Nicot who introduced tobacco to the royal court of Paris in the 16
th
 century.  Tobacco was 
used for the first time in England around the year 1565 and later was taken to Italy, Germany 
and Russia in the year 1600 (Hoffmann and Hoffmann, 1997).  
 
2.3.2.Tobacco smoke streams and constituents 
Smoking a cigarette releases an aerosol composed of a complex and dynamic mixture of 
compounds grouped into a vapor phase or a particulate phase (Hoffmann and Hoffmann, 
1997). The vapor phase contains the volatile components such as carbon dioxide, carbon 
monoxide, acrolein, toluene, benzene and acetylene. The particulate phase contains more 
than 4000 compounds including more than 50 carcinogens (Hoffmann and Hoffmann, 1997; 
Smith et al., 2003). These comprise the semi-volatile and non-volatile components of the 
aerosol such as nicotine, naphthalene and pyrene (Hoffmann and Hoffmann, 1997; Smith et 
al., 2003). Three streams of cigarette smoke are generated as results of smoking i.e. main 
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stream smoke, side stream smoke and environmental tobacco smoke (ETS) (Borgerding and 
Klus, 2005). Main stream smoke is the smoke actively inhaled by the smoker from the filter 
end of a cigarette. Side stream smoke is generated from the burning end of a cigarette. 
Environmental tobacco smoke is a mixture of side stream smoke, smoke exhaled from the 
lung of a smoker and ambient air. It has been shown that the toxicity of aging sidestream 
smoke may be much greater than that of an equivalent mass dose of mainstream smoke 
(Schick and Glantz, 2006). In general, some compounds present in main stream smoke are 
similar to those found in ETS. However, differences in concentrations as well as physical and 
chemical properties have been reported. The exhaled portion of main stream smoke 
contributes only 15%-43% of the particulate matter of ETS with the rest originating from 
side stream smoke (Borgerding and Klus, 2005). Similarly, the majority of vapor phase 
constituents of ETS are derived from side stream smoke with only 1-13% coming from the 
exhaled portion of main stream smoke (Eatough DJ, 1990). The mean diameter of particles 
within main stream smoke is 0.27 +/- 0.03 µm, while the mean diameter of side stream 
smoke is 0.09 +/- 0.01 µm (Becquemin et al., 2007). Approximately, 90-96% of the weight 
of the main stream smoke originates from the vapor phase, which contains 400-500 gaseous 
compounds (Hoffmann and Hoffmann, 1997; Hoffmann et al., 2001). Oxygen, nitrogen and 
carbon dioxide are the main constituents of this phase (Hoffmann et al., 2001). Several 
carcinogenic compounds including nitrogen oxides, isoprene, butadiene, benzene, styrene, 
formaldehyde, acetaldehyde, acrolein and furan can also be found (Hoffmann et al., 2001). 
The remaining 5% of the smoke weight is present in the particulate phase (Hoffmann and 
Hoffmann, 1997; Hoffmann et al., 2001). The particulate phase contains at least 3500 
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compounds. Nicotine is the major constituent of this phase comprising 0.2-0.6% of the total 
smoke weight (Hoffmann and Hoffmann, 1997; Hoffmann et al., 2001).  
The long term health effects of cigarette smoke constituents are largely controversial. For 
example, it has been shown that nicotine exposure not only decreases the production and 
bioavailability of NO (Fang et al., 2003), but also increases the levels of asymmetric 
dimethyl arginine, an endogenous inhibitor of eNOS (Hamasaki et al., 1997). However, 
others also found that nicotine promotes endothelial survival and release of vasodilators 
(Villablanca, 1998). Similarly, the exposure to carbon monoxide at low concentrations 
protects against oxidative stress and inhibits atherogenesis (Orozco et al., 2007; Ryter et al., 
2006). Others also reported that carbon monoxide decreases oxygen delivery to tissues, 
blocks the mitochondrial respiratory chain (Kumar V, 2010), accelerates atherosclerosis 
(Paule et al., 1976) and promotes cardiac hypertrophy (Sørhaug et al., 2006).  In addition the 
particulate phase contains many carcinogenic polycyclic aromatic hydrocarbons (PAHs) such 
as benzo[a]pyrene (BAP) (Hoffmann and Hoffmann, 1997; Hoffmann et al., 2001) which 
have deleterious health effects. These effects will be discussed later. 
 
2.3.3.Tobacco smoke statistics and general health effects 
Smoking continues to be a worldwide problem with negative health, economic and social 
effects. There are more than one billion smokers worldwide, with cigarette smoking killing 
more than 5 million people annually (Yach and Wipfli, 2006). Cigarette smoking is the 
leading cause of death in the US and accounts for nearly 1 of every 5 deaths each year 
(Mokdad et al., 2004). In fact, the number of deaths related to tobacco smoking exceeds all 
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other deaths due to human immunodeficiency virus, illegal drug use, alcohol use, motor 
vehicle injuries, suicides, and murders combined (Center for Disease Control and Prevention, 
2003; Mokdad et al., 2004). In 1998, cigarette smoking killed 30,230 men and 17,351 
women in Canada, of which 1,107 died due to second hand smoke exposure. The main 
causes of smoking-related deaths were lung cancer (13,951 deaths), ischemic heart disease 
(9,289 deaths) and chronic airways obstruction (6,457 deaths) (Makomaski Illing and 
Kaiserman, 2004). 
The adverse effects of cigarette smoking involve almost every organ in the body. Chronic 
tobacco smoking is considered a major contributing factor towards many health problems, 
particularly cardiovascular and lung diseases (Center for Disease Control and prevention, 
2003). Smoking increases the risk of many CVDs, including coronary heart disease, stroke, 
peripheral artery disease, hypertension, and aortic aneurysm (Bartal, 2001). A large 
epidemiologic study including 21 countries found that smokers under the age of 40 had a five 
times greater risk of heart attack compared to nonsmokers (Mahonen et al., 2004). The risk 
of cerebral stroke is approximately doubled in smokers (Ockene and Miller, 1997).  
The effects of cigarette smoking on the lungs have been thoroughly investigated. 
Smoking is a major risk factor for the development of chronic obstructive pulmonary disease 
(COPD) (Sharafkhaneh et al., 2008). ETS exposure negatively influences the outcome of 
COPD in nonsmokers (Eisner et al., 2006; Eisner et al., 2009) Tobacco smoking is 
responsible for 90% and 80% of lung cancer deaths in women and men, respectively (Hecht, 
1999). Countless number of epidemiological studies reported an association between tobacco 
smoking and several types of cancer (Sasco et al., 2004). In fact, almost one third of cancer 
related deaths in the US are attributed to smoking (Shopland et al., 1991). A positive 
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correlation has been shown between tobacco smoking and cancers of the lung, oral, cavity, 
pharynx, larynx, esophagus, pancreas, urinary bladder and renal pelvis (Sasco et al., 2004). 
Tobacco smoking is also connected to sudden infant death syndrome and results in reduced 
memory and cognitive abilities in adolescent smokers (Anderson et al., 2005; Jacobsen et al., 
2005). In comparison to smoking, the effects of ETS are less clearly established. 
 
2.3.4.Smoking and cardiovascular disease 
2.3.4.1.Epidemiologic evidence 
Strong association between cigarette smoking and CVD has been reported in several 
studies. It is estimated that 30% of deaths due to coronary heart disease are related to 
cigarette smoking (Ambrose and Barua, 2004). Additionally, the risk of ischemic stroke is 
doubled in smokers compared to nonsmokers (Shinton and Beevers, 1989). Smokers are also 
at increased risk of claudication, abdominal aortic aneurysm and amputation than 
nonsmokers (Krupski, 1991). The exposure to ETS has also been linked to CVD. The risk of 
CVD is increased by 30% in people exposed to ETS (Center for Disease Control and 
Prevention, 2006).  
 
2.3.4.2.Mechanisms of cigarette smoke induced cardiovascular disease 
2.3.4.2.1.Endothelial dysfunction 
Several studies reported the presence of morphological changes within endothelial cells 
after cigarette smoke or one of its constituents. Rat endothelial cells exposed in vitro to 
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nicotine at concentrations similar to those of smokers displayed subendothelial edema, 
swollen endoplasmic reticulum, and increased numbers of mitochondria (Pittilo et al., 1990).  
Aortic endothelial cells exposed in vitro to cigarette smoke extract displayed decreased 
eNOS activity and increased production of superoxide anion and peroxynitrite (Peluffo et al., 
2009a). Additionally, FMD was impaired in smokers compared to nonsmokers, an 
impairment which could be reversed by the administration of antioxidants for 165days 
(Peluffo et al., 2009a). Similarly ETS exposure in 11 year–old children resulted in impaired 
endothelial function, measured as FMD, in a dose-dependent manner (Kallio et al., 2007). 
The mechanism of FMD impairment and endothelial dysfunction is thought to be related to 
increased eNOS uncoupling, decreased NO production and bioavailability (Fang et al., 
2003).  
 
2.3.4.2.2.Pulmonary inflammation and oxidative stress in smoking 
The deposition of smoke particles within the lung is dependent on their particle size, with 
smaller particles penetrating deeper into the pulmonary system (Bernstein, 2004). Several in 
vivo and in vitro studies have shown that cigarette smoke exposure causes localized lung as 
well as systemic inflammation (Eileen, 2006). Cigarette smoke particles, first, cause injury to 
resident cells within the lung, stimulating them to release chemotactic factors, and 
inflammatory mediators. This results in the increased expression of adhesion molecules on 
the surface of endothelial cells as well as the activation of neutrophils to allow their entry 
into the lung.  
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Histologically, the lungs of smokers contain large numbers of pigmented and fluorescent 
macrophages associated with the ingestion of the tar component of cigarette smoke (Pauly et 
al., 2005).  Accumulations of polymorphonuclear cells have also been reported (Eileen, 
2006). Tobacco smoking is also known to cause inflammation within the oral cavity (Taybos, 
2003).  The effects of cigarette smoke exposure on markers of oxidative stress have also been 
evaluated in exhaled air and bronchoalveolar lavage (BAL) fluid from smokers. In breath 
condensate from smokers the levels of 8-isoprostane, a marker of lipid peroxidation, as well 
as the levels of hydrogen peroxide are increased (Guatura et al., 2000; Montuschi et al., 
2000). Within BAL fluid the levels of oxidized glutathione and superoxide are also increased 
(Morrison et al., 1999; Nagai et al., 2006). The breath condensate of smokers also has 
increased levels of leukotriene B4 (LTB-4) and IL-6 (Carpagnano et al., 2003). High levels 
of IL-8 have also been reported (Tanino et al., 2002). Within the peripheral blood the level of 
LTB-4 increased significantly after acute exposure to cigarette smoke (Kobayashi et al., 
1988). IL-8 and LTB-4 attract neutrophils toward the alveoli (Kumar V, 2010). In animal 
models, the exposure to cigarette smoke results in the recruitment of neutrophils and 
macrophages toward the lung (Kilburn and McKenzie, 1975). In lung tissue, the expression 
levels of macrophage inflammatory protein-1 (MIP-1), and macrophage chemoattractant 
protein-1 (MCP-1) and tumour necrosis factor-α (TNF-α) have been shown to increase after 
cigarette smoke exposure (Wright et al., 2002). MCP-1 and MIP-1 are chemotactic for 
macrophages. The release of TNF-α from alveolar macrophages is  increased when they are 
exposed to a high concentration of cigarette smoke extract (Churg et al., 2003).  
Additionally, peripheral blood mononuclear cells and macrophages exposed in vitro to  
cigarette smoke release interleukin-1β (IL-1β) and TNF-α (Ryder et al., 2002). IL-1β and 
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TNF-α can enhance the recruitment of inflammatory cells by increasing the expression, 
synthesis, and release of several cytokines and cell
 
adhesion molecules by other cells 
(Dinarello, 2000; Mills et al., 1999). Epithelial cells also contribute to cigarette smoke- 
induced lung inflammation. Moreover, normal human bronchial epithelial cells exposed to 
cigarette smoke condensate display increased mRNA levels of IL-1β, IL-8 and GM-CSF 
(Hellermann et al., 2002). This is thought to be mediated by the activation of extracellular 
signal-regulated protein kinase-1/2  and nuclear factor κB (Hellermann et al., 2002). 
Cigarette smoke exposure increases airway permeability by affecting the integrity of tight 
junctions between epithelial cells (Morrison et al., 1999). The disruption of tight junctions 
results in the accumulation of smoke constituents within the subepithelial region (Bhalla et 
al., 2009). The slow clearance of smoke particles within this region causes not only increased 
retention of carcinogens within the lung, but also extended release of particulates from the 
lung toward the systemic circulation. This slow and continuous release of smoke constituent 
particles causes a short cigarette smoke exposure to mimic a chronic exposure scenario 
(Bhalla, 1999). Additionally, it has been shown that oxidants in the gas phase of cigarette 
smoke have the ability to pass through alveolar wall and raise systemic oxidative stress 
(Yamaguchi et al., 2007). The increased systemic inflammatory response and oxidative stress 
due to active or passive smoking alters endothelial function and increase the risk for CVD.  
Cigarette smoke exposure is an important risk factor for COPD (Higgins, 1991). Smokers 
with COPD often have histological evidence of chronic bronchitis and alveolar emphysema 
(Selman, 2003). The inflammatory response to cigarette smoke exposure includes the release 
of elastases and metalloproteinases from macrophages and neutrophils within the lung 
(Churg et al., 2008). These include neutrophil elastase, metalloproteinase-9 (MMP-9), 
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produced by macrophages and neutrophils, and metalloproteinase-12 (MMP-12) produced by 
macrophages (Churg et al., 2008).  It has been shown that guinea pigs given an inhibitor of 
MMP-9 and MMP-12 are protected from cigarette smoke-induced alveolar emphysema 
(Churg et al., 2007). These enzymes not only destroy the extracellular matrix but also help 
regulate inflammation through the release of cytokines and chemokines (Van Lint and Libert, 
2007).  In comparison to smoking the effects of ETS are less clearly established. 
 
2.4. Polycyclic aromatic hydrocarbons (PAHs) 
The polycyclic aromatic hydrocarbons are a group of lipophilic and persistent 
environmental contaminants that arise as by-products of combustion of organic matter 
(Tithof et al., 2002). This family of contaminants contains compounds like naphthalene and 
anthracene (Haritash and Kaushik, 2009). Polycyclic aromatic hydrocarbons are used 
extensively in laboratory animals to induce neoplastic transformation in tissues and the 
prototypical carcinogen is a reactive metabolite of the PAH, BAP (Nebert et al., 2000)  
 
2.4.1.Mechanism of action of polycyclic aromatic hydrocarbons 
Many of the actions of PAHs are mediated by a ligand-activated transcription factor 
known as the aryl hydrocarbon receptor (Ahr) (Korashy and El-Kadi, 2006). Ahr binds to the 
xenobiotic response element on DNA, and causes transcriptional induction of dioxin-
responsive genes such as the detoxification enzyme cytochrome P450 1A1 enzyme 
(CYP1A1) (Korashy and El-Kadi, 2006). The first step in the metabolism of PAHs is 
epoxidation, which is mediated by CYP1A1 (Levin et al., 1982). PAH epoxides are then 
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converted to diols through the enzyme epoxide hydrolase. The oxidation of PAHs to 
epoxides results in the formation of highly reactive metabolites which can form protein and 
DNA adducts leading to cancer development (Levin et al., 1982). Furthermore, quinone 
metabolites of PAHs are capable of redox cycling and can generate large amounts of ROS 
(Korashy and El-Kadi, 2006; Moorthy et al., 2003). The expression of CYP1A1 in tissues is 
also used as a marker of exposure to contaminants that activate Ahr. Ahr stimulation within 
the lung, liver or endothelial cells results in high expression levels of CYP1A1 (Brunnberg et 
al., 2006; Kopf and Walker, 2010). This can be used in mechanistic investigations of toxicity 
since only the parent PAH compounds can activate Ahr, while their metabolites generally 
cannot (Nebert et al., 2000). 
 
2.4.2.Polycyclic aromatic hydrocarbons within cigarette smoke 
The particulate phase of cigarette smoke contains many of the PAHs like 
benzo[a]antharacene, benzo[b]fluoranthene, benzo[j]fluoranthene and BAP (Hoffmann and 
Hoffmann, 1997). The levels of PAHs within side stream smoke are reported to be 10 times 
higher than that in main stream smoke (Lodovici et al., 2004), potentially making PAH-
mediated effects more relevant to ETS than to smoking.  
 
2.4.3.Polycyclic aromatic hydrocarbons and cardiovascular disease 
There is accumulating evidence that PAH exposure enhances the development of 
atherosclerosis. It has been shown that in the absence of toxicant, an increase in shear stress 
results in CYP1A1 induction and cell cycle arrest of endothelial cells which is mediated by 
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Ahr activation (Han et al., 2008). However, there is virtually no knowledge of the normal 
physiological role, if any, of Ahr in CV physiology. In human beings, a correlation between 
the exposure to PAHs and the development of ischemic heart disease has also been found 
(Burstyn et al., 2005). High levels of DNA adducts associated with PAHs have been found in 
atherosclerotic plaques of human beings (Izzotti et al., 1995). Moreover, patients with 
advanced atherosclerotic lesions have higher levels of aortic DNA adducts compared to 
patients with mild or moderate atherosclerotic lesions (Binková et al., 2002). Experimentally, 
the exposure to PAHs accelerates the development of atherosclerosis (Penn and Snyder, 
1988), which could be related to increased oxidative stress (Nebert et al., 2000), and 
increased adhesiveness of endothelial cells (Oesterling et al., 2008). The most widely studied 
member of the PAH family of compounds is BAP. BAP was also the first carcinogen 
identified in cigarette smoke (Commins et al., 1954). Similar to other PAHs, BAP is 
metabolized to 7,8-epoxide by the enzyme CYP1A1. The enzyme epoxide hydrolase 
converts 7,8-epoxide to 7,8-diol. It is then the secondary oxidation of 7,8-diol by CYP1A1 
which converts BAP to the ultimate carcinogen BAP 7,8-diol-9,10-epoxide (Moorthy et al., 
2003). Additionally, BAP can be metabolized to quinone structures by CYP1A1 which can 
undergo redox cycling to produce ROS (Korashy and El-Kadi, 2006; Moorthy et al., 2003). 
The administration of BAP to apolipoprotein E- knockout mice results in endothelial 
proinflammatory effects i.e. induces expression of MCP-1 (Knaapen et al., 2007), and 
accelerated lipid peroxidation (Godschalk et al., 2003). Inhaled PAHs also cause 
inflammatory reactions within the lung (Belitskaya-Levy et al., 2007; Pei et al., 2002). 
Therefore, it seems plausible that PAHs such as BAP may be responsible for the increased 
CVD risk posed by smoking tobacco and chronic exposure to ETS. 
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2.5. Resveratrol (RES) 
Natural antioxidants, within fruits and vegetables, such as  RES, sulphoraphane and many 
others,  have received increasing attention in recent years because of their role in protecting 
against CVD, cancer, and inflammation (Kode et al., 2008). Resveratrol is a polyphenolic 
compound found in several types of fruits with antioxidant (Kawada et al., 1998), anti-
inflammatory (Donnelly et al., 2004), and anti-carcinogenic properties (ElAttar and Virji, 
1999). The interest in RES arose after a study in the early 1990s which pointed to a link 
between the low mortality among the French population from coronary heart disease 
compared to North Americans, despite much higher smoking rates, and the consumption of 
red wine; the so-called “French paradox” (Renaud and de Lorgeril, 1992). The cardio-
protective property of red wine was attributed to RES. Additionally, it has been reported that 
RES attenuates cigarette smoke-induced oxidative stress and proinflammatory phenotypic 
alterations within endothelial cells (Csiszar et al., 2008). Our interest in RES, versus other 
natural antioxidants, stems from the claim that red wine consumption, and thus RES, is 
protective for the cardiovascular system and may also reverse the negative effects of cigarette 
smoke.  
 
2.5.1.Resveratrol structure and metabolism 
Resveratrol or 3,5,4’-trihydroxystilbene  is a natural antioxidant present in grapes, 
peanuts and different species of berries such as blueberries, bilberries, and cranberries (Burns 
et al., 2002). The skin of grapes contains 50-100 µg/g RES (Ector et al., 1996). Despite its 
high absorption (70%), only trace amounts of unchanged RES is found in plasma, which is 
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due to extensive and rapid liver metabolism. A dose of 25mg (110 µmol) given orally 
resulted in a peak concentration of resveratrol and metabolites in plasma of 491±90 ng/ml. 
However, unchanged RES levels were very low in plasma (< 5ng/ml). The half-life of 
unchanged RES was 8-14 minutes while the half-life for its metabolites was 9.2±0.6h. Three 
metabolic pathway of RES have been identified i.e. sulfation, glucuronic acid conjugation 
and hydrogenation  (Walle et al., 2004). The biologic effects of these metabolites are 
unknown. 
 
2.5.2.Resveratrol’s health effects and mechanisms of action 
Sirtuins are a family of nicotinamide adenine dinucleotide (NAD
+
)-dependent protein 
deacetylases (Lin et al., 2000). The member silent information regulator 2 (Sir2) is found in 
budding yeast Saccharomyces cerevisiae. Calorie restriction to this yeast has been shown to 
prolong its lifespan, which is thought to be mediated by Sir2 activity (Lin et al., 2000). Sirt-1 
is mammalian homologue of Sir2 (Cohen et al., 2004). Sirt-1 deacetylates histones associated 
with several important transcriptional factors and thus alters their function. For example Sirt-
1 deacetylates the protein P-53 making it inactive, preventing cells from undergoing 
apoptosis and therefore increasing their life span (Yang et al., 2006). Resveratrol is known to 
be a potent activator of Sirt-1 and hence is claimed to increase life span in mammals (Borra 
et al., 2005). Resveratrol is reported to be antiatherosclerotic with much of this effect 
attributed to its antioxidant activity (Sarfaraz and Rohit, 2009). Resveratrol can decrease 
plasma lipid concentration in apolipoprotein E-deficient, hypercholesterolemic rats (Fukao et 
al., 2004). Through copper chelation, RES also decreased the copper-mediated oxidation of 
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LDL thus inhibiting atherosclerosis (Belguendouz et al., 1997). Additionally RES decreases 
vascular oxidative stress by inhibiting vascular NADPH oxidase enzyme (Orallo et al., 
2002). The recruitment of monocytes to the vasculature may also be reduced by RES 
treatment. Human umbilical vein endothelial cells incubated with RES and later with 
bacterial lipopolysaccharide display not only decreased oxidative stress, but also reduced 
VCAM-1 mRNA and protein expression (Carluccio et al., 2003). Resveratrol also decreases 
the angiotensin II-induced proliferation of vascular smooth muscle cells (Haider et al., 2003).  
It has been reported that RES is also a vasodilator since phenylephrine-induced aortic 
contraction is inhibited by RES treatment (Chen and Pace-Asciak, 1996). Moreover, RES has 
been found to antagonize the effects of the potent vasoconstrictor, endothelin (Yang et al., 
1998). Resveratrol is also known to be an Ahr antagonist as it blocks the induction of 
CYP1A1 by dioxins (Ciolino et al., 1998).  
A few studies are doubtful about the cardioprotective effects of RES. It has been reported 
that RES given to rats does not prevent peroxidation of serum lipids and has no effect on 
lipoprotein profile (Turrens et al., 1997). Others have also found that RES possesses pro-
oxidant properties and in the presence of transition metals, such as copper, can result in 
oxidative DNA break down (de la Lastra and Villegas, 2007). Two pharmaceutical 
companies i.e. Amgen and Pfizer, recently challenged the claims of beneficial health effects 
of RES reporting that RES is not an activator of Sirt-1 (Beher et al., 2009; Pacholec et al., 
2010) and does not decrease serum glucose levels in mice fed high fat diet (Beher et al., 
2009; Pacholec et al., 2010). Therefore, not only is the mechanism of action of RES in the 
CV system unclear, but also the health benefits are yet to be clearly established. 
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3. Hypotheses and research objectives 
3.1. Hypothesis  
1. Pigs are a good model to study and detect cardiovascular and lung changes after 
chronic ETS exposure. 
2. Chronic ETS exposure results in systemic inflammation and oxidative stress 
leading to vascular endothelial dysfunction and cardiac dysfunction as well as 
lung inflammation and emphysema in swine.  
3. Chronic exposure to BaP, a PAH within cigarette smoke, will mimic the ETS- 
induced health effects in swine.  
4. Resveratrol, a natural antioxidant, will protect against the ETS- induced health 
effects in swine.  
3.2. Objectives 
3.2.1  To examine the feasibility of using pigs as a model to detect cardiovascular and 
lung changes after chronic ETS exposure. 
3.2.2  To examine the effects of chronic ETS exposure on markers of systemic oxidative 
stress and inflammation, vascular endothelial function, cardiac function, lung 
inflammation and emphysema.  
3.2.3  To examine the health effects of chronic exposure to BAP, a PAH found in ETS, 
and to check if it mimics the effects induced by ETS. 
3.2.4  To examine whether RES, a natural antioxidant, protects against the ETS induced 
health effects. 
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4. Pulmonary inflammation and Cytochrome P450 1A1 activity are 
linked to endothelial dysfunction after ETS exposure, but not 
after benzo-a-pyrene injection in juvenile pigs 
4.1. Introduction 
The adverse health effects of cigarette smoke involve almost every organ system in 
smokers (Alberg, 2008; Bartal, 2001). However, cardiovascular and respiratory effects are 
most prevalent including diseases such as atherosclerosis, coronary artery disease, asthma, 
and COPD (Armani et al., 2009; Bhalla et al., 2009).  Exposure to second-hand tobacco 
smoke, also referred to as ETS, poses an increased risk for many of these same diseases. In 
fact, smoking and ETS exposure are considered the number one preventable risk factor 
contributing to CVD.  
Endothelial cells play a key role in the regulation of vascular tone and impairment of 
normal endothelial function is thought to be an early step in the development of all CVD, 
including in smokers (Luscher, 1994). Endothelial dysfunction causes impaired vascular 
relaxation which in turn increases peripheral vascular resistance and contributes to 
atherosclerosis (Walsh et al., 2009). An increase in vascular tone and hemodynamic overload 
would also cause myocardial systolic dysfunction because the heart has to work harder to 
eject blood against the increased afterload (Borlaug et al., 2009). Furthermore, a prolonged 
increase in afterload causes left ventricular hypertrophy and alteration in left ventricular 
extracellular matrix (Verma and Solomon, 2009) which would then contribute to diastolic 
dysfunction. In support of this, several studies have provided evidence that acute and chronic 
exposure to cigarette smoke impair left ventricular diastolic function (Alam et al., 2002; 
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Gulel et al., 2007). Therefore, assessing endothelial function has become increasingly 
important as a prognostic clinical tool and method used in mechanistic investigations of  
cardiovascular pathophysiology (Harris et al., 2010). Flow mediated dilation is an 
endothelium dependent ultrasound technique which measures the ability of conduit arteries to 
relax and expand in response to a shear stress stimulus. Flow mediated dilation has been used 
as an early predictor for CVD (Martin, 2009) and is thought to be mediated largely by NO. 
Flow mediated dilation has been shown to be impaired in smokers which might be related to 
decreased NO bioavailability (Celermajer et al., 1996; Karatzi et al., 2007; Peluffo et al., 
2009b). However, the effect of ETS on endothelial function is less clearly established. 
Cigarette smoke-induced oxidative stress is a major pathway contributing to the 
development of CVD (Minicucci et al., 2009; Vardavas and Panagiotakos, 2009). 
Peroxynitrite is produced as a result of the interaction between superoxide anion and NO 
(Ischiropoulos and al-Mehdi, 1995; van der Vliet et al., 1995) which leads to reduced NO 
bioavailability and impaired vasodilation (Peluffo et al., 2009b). Cigarette smoke exposure 
also results in increased serum 3-nitrotyrosine levels, which is generated by the nitration of 
tyrosine residues within proteins by peroxynitrite (Kunitomo et al., 2009). Additionally, 
epidemiologic studies have shown that cigarette smokers have higher levels of CRP in their 
serum, compared to non smokers (Antoniades et al., 2004; Hanyu et al., 2009). C-reactive 
protein is an acute phase protein elevated during inflammation (Antoniades et al., 2004) and 
individuals with high CRP serum levels are at increased risk of developing CVDs (May and 
Wang, 2007).  
Cigarette smoke is a mixture of more than 4000 compounds and contains different classes 
of toxic chemicals including PAHs (Borgerding and Klus, 2005; Ding et al., 2008). Although 
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nicotine is the constituent that is responsible for cigarette smoke addiction and is known to 
exert many stimulatory actions on the cardiovascular system (Rahman and Laher, 2007), it 
does not explain the chronic effects of cigarette smoke or ETS exposure (Rahman and Laher, 
2007). Polycyclic aromatic hydrocarbons are lipophilic compounds which result from the 
combustion of organic material (Tithof et al., 2002). Many of the actions of PAHs are 
mediated by a ligand activated transcription factor known as the Ahr (Korashy and El-Kadi, 
2006). By binding to the xenobiotic response element on DNA, this transcription factor 
causes transcriptional induction of dioxin-responsive genes such as the detoxification enzyme 
cytochrome P450 1A1 enzyme (CYP1A1) (Korashy and El-Kadi, 2006). The metabolism of 
PAHs, such as BAP, by CYP1A1 results in the formation of highly reactive metabolites 
which, in turn, can form adducts with DNA and protein (Korashy and El-Kadi, 2006; 
Moorthy et al., 2003). Additionally, PAH metabolites can be metabolized to quinone 
structures which can undergo redox cycling to produce ROS (Korashy and El-Kadi, 2006; 
Moorthy et al., 2003). Tobacco smoke also contains carbon monoxide and many unstable, 
reactive molecules that would increase the levels of carboxyhemoglobin (CO-Hb) and 
methemoglobin (MetHb), respectively, after tobacco smoke exposure (Borland et al., 1985). 
In addition to known vasodilatory effects of CO (Achouh et al., 2008), it has been shown that 
endothelial cells produce peroxynitrite after CO exposure (Thom et al., 1997), suggesting 
that CO by itself can also stimulate oxidative stress. Therefore, there are multiple chemical 
sources of oxidative stress arising from cigarette smoke.  
Oxidative stress can also be produced as a result of inflammation (van der Vaart et al., 
2004). Active cigarette smoking is known to induce lung inflammation as evidenced by the 
presence of neutrophils and macrophages within alveoli (van der Vaart et al., 2004). 
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Inflammation within the airways is also known to promote decreased lung function, asthma 
and respiratory irritation in children and adults passively exposed to ETS (Chan-Yeung and 
Dimich-Ward, 2003; Salvi and Barnes, 2009). Pulmonary neutrophils and macrophages not 
only generate ROS and inflammatory cytokines, but also release extracellular matrix 
degrading enzymes i.e. elastases which contribute to lung emphysema (Sharafkhaneh et al., 
2008). Although the exact identity and mechanisms responsible are not clear, these 
inflammatory mediators originating in the lung may also travel systemically to cause further 
inflammation in distal tissues, particularly in the endothelium of the vasculature (Tamagawa 
et al., 2008). Thus, pulmonary inflammation caused by ETS exposure may be a central 
mechanism responsible for the increased incidence of both pulmonary disease as well as 
CVD.  
We hypothesized that chronic exposure to ETS would result in lung and systemic 
inflammation which in turn would result in increased oxidative stress, endothelial 
dysfunction, impaired FMD, increased blood pressure, impaired left ventricular function and 
increased broncho-alveolar elastase associated with emphysema. We also hypothesized that 
these effects could be mimicked by BAP exposure. In order to evaluate this hypothesis we 
first randomized 8 castrated male pigs into two groups and performed daily 1-hr ETS- or 
sham-exposures for 28 days. Another 8 pigs received either a daily intravenous BAP or 
vehicle injection for 7 days. Flow mediated dilation, left ventricular end systolic volume 
(ESV), end diastolic volume (EDV), ejection fraction (EF), mean arterial pressure, systolic 
pressure, diastolic pressure, CO-Hb, oxyhemoglobin (OxyHb), MetHb, total hemoglobin 
(TotalHb), serum nitrate/nitrite (NOx), nitrotyrosine, CRP, liver CYP1A1 and lung CYP1A1 
were measured. Total and differential cell count, and neutrophil elastase level in 
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bronchoalveolar lavage (BAL) fluid were performed at the termination of both experiments. 
Histological and morphometric analyses were also performed on the abdominal aorta, 
brachial, and coronary arteries, while lung, liver and heart were evaluated for 
histolopathology.    
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4.2. Materials and methods 
4.2.1.Animals  
All protocols were in accordance with the Canadian Council on Animal Care guidelines 
and were approved by the Animal Care and Use Council at the University of Saskatchewan. 
In each experiment, 2 week old, castrated male landrace pigs (10-12 kg) were obtained from 
Prairie Swine Center Inc (Saskatoon, SK) and randomized into exposure or sham groups 
(4/group).  The pigs were group-housed with each treatment group kept in separate pens 
under a 12 hr dark/12 hr light cycle. Pigs were fed normal pig starter chow (Federated Co-
Operatives Ltd, Saskatoon, Canada) and water ad libitum except during exposure, injection 
or cardiovascular assessment.  
 
4.2.2.Environmental tobacco smoke (ETS) and benzo[a]pyrene (BAP) exposure 
In the first experiment, a single cigarette manual smoking machine from CH 
Technologies Inc (Westwood, NJ, USA) was used to generate ETS (mainstream plus side 
stream smoke). The machine was adjusted to a rate of 3 puffs/minute with 57 ml/puff and a 2 
second duration. The ETS, mixed with unfiltered indoor air, was then pumped into a 500 
gallon polyethylene plastic water tank modified to include inflow and out flow ports and a 
sealed, removable plexiglass door in which unsedated, unrestrained pigs (n=4 per group) 
were exposed. Pumps controlling inflow were set at 6 L/min. A total of 12 cigarettes 
(Filtered Canadian Classics, Rothmans, Benson & Hedges, Canada) were burned over the 
span of 1 hr every day for 28 days. Sham-exposed pigs (n=4) were placed in the same 
cleaned chamber for an hour but with an unlit cigarette attached to the smoking machine. The 
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total particulate count in the chamber was assessed  for the ETS-exposed and sham-exposed 
pigs using a SKC constant airflow pump (Universal 224-PCXR, Eighty Four, PA) fitted with 
pre-weighed mixed cellulose ester filter (0.08 μm, SKC Inc., Eighty Four, PA).  Total 
particulates were sampled continuously for one hour at 2L/min. Carbon monoxide levels 
were also monitored in both groups using a T40 Rattler CO monitor (Industrial scientific, 
Corp, Oakdale, USA) placed inside the chamber for the duration of the exposure. The air 
levels of O2/CO2 within the chamber were measured using a Criticare Poet IQ 
multiparameter gas monitor (Criticare Systems, Inc., Waukesha, USA). In the second 
experiment, pigs received a daily intravenous injection of BAP (5 mg/kg) (Sigma-Aldrich, 
St. Louis, USA, 96%) via the anterior vena cava for 7 days. Control pigs received the same 
volume of a vehicle control (0.2 ml/kg tricaprylin, T9126, Sigma-Aldrich, St. Louis, USA, 
99%) daily for the same period. 
4.2.3.Flow mediated dilation (FMD), echocardiography, blood pressure, and blood 
gas evaluation 
Because FMD has not previously been reported in pigs, FMD measurements were 
validated (n=8 pigs) in preliminary experiments. Pigs were first sedated by receiving an 
intramuscular injection of azaperone (2.2 mg/kg, Stresnil™ Merial Inc, Canada). Pigs were 
placed in left lateral recumbency. The left brachial artery was visualized using a SonoSite 
180 Plus ultrasound unit with a 5.0 MHz linear array transducer (SonoSite Canada Inc., 
Markham, Ont., Canada). The probe was placed on the medial aspect of the distal third of the 
left radius, approximately 10 centimeters from the axilla. The blood pressure cuff was 
applied directly distal to the ultrasound area. The brachial artery was visualized at baseline 
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(unoccluded) in order to extract a minimum of 3 images that were averaged and this average 
value was used as the baseline diameter. The blood pressure cuff was then inflated to 30 
mmHg above systolic pressure for 4 minutes. Following cuff release the brachial artery was 
visualized for 150s. All ultrasound views were recorded using a digital video camera for the 
duration of the post-occlusion time and uploaded to a computer. Single digital images of the 
brachial artery at diastole were extracted at 15s, 30s, 45s, 60s, 75s, 90s, 105s, and 120s after 
cuff release using Adobe Premiere Elements (Adobe Inc., San Jose, CA, USA). The 
perimeter (P) of the brachial artery at each time point was traced and measured using Image-
Pro Plus (Media Cybernetics Inc., Bethesda, MD, USA) (Figure 4.1) and converted to a 
diameter using the formula: diameter = P/ . All measurements of digital ultrasound images 
were performed blinded. The flow mediated dilation was calculated using the formula: 
% FMD = (post-occlusion diameter) – (baseline diameter) x 100% 
                                        (baseline diameter) 
For exposure experiments, at the beginning of each ultrasound session, pigs were sedated as 
previously described and the rectal temperature was measured using a thermometer 
immediately after ETS /sham exposure or BAP/vehicle injection. The flow mediated dilation 
evaluation was performed as described above. The left ventricular end-systolic volume 
(ESV) and end-diastolic volume (EDV) were measured using an HP SONOS 100CF 
ultrasound machine.  A 5.0 MHz cardiac transducer was used in the right parasternal long-
axis view to visualize the left ventricular outflow tract during systole and diastole. For each 
end point two measurements were taken and then averaged. The ejection fraction (EF) was 
calculated using the formula: 
EF = [(EDV – ESV) / (EDV)] × 100%
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A                                                                       B                              
                                    
C                                                                           D 
   
 
Figure 4.1: Ultrasound probe and cuff placement for brachial artery flow mediated dilation  
evaluation (A).  Brachial artery ultrasound images at baseline (B), 60s (C) and 90s (D) after 
cuff release. 
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After vascular and cardiac ultrasound, a Memo Diagnostic High Definition Oscillometer 
(S + B medVET, Markham, Ont. Canada) was placed on the distal end of the right hind limb 
to measure systolic pressure, diastolic pressure, mean arterial pressure (MAP) and heart rate. 
The mean of at least 3 consecutive blood pressure readings from each pig was used from a 
given session for statistical analyses. Finally, blood gases were measured in venous blood 
collected from the jugular vein into blood gas syringes (Radiometer PICO 50; Radiometer; 
Copenhagen, Denmark). Oxygenated hemoglobin (oxyHb), carboxy-hemoglobin (CO-Hb), 
methemoglobin (MetHb) and total hemoglobin (TotalHb) levels were measured using a 
Rapidlab 865 blood gas analyzer (Bayer Diagnostics, East Walpole, MA, USA). Ultrasound, 
blood pressure and blood gas measurements were taken at baseline (i.e. Day 0 or prior to 
starting the exposures), day 1, day 7, day 14, day 21 and day 28 for the ETS experiment.  In 
the second experiment the same parameters were measured at baseline, day 1 and day 7. 
 
4.2.4.Plasma nitrate/nitrite, cotinine, nitrotyrosine, C-reactive protein (CRP), and 
ethoxyresorufin-o-deethylase (EROD) activity 
Blood samples were collected from the right anterior vena cava from all pigs at baseline 
and on the last day of experiments into EDTA or serum Vacutainers for plasma and serum, 
respectively, and stored on ice until spun at 4000xg for 10 minutes. Plasma and serum were 
aliquoted, then stored at -80C until use in assays. Plasma nitrate/nitrite (NOx) levels were 
assessed using a commercially available enzyme-based kit (NO Quantitation Kit, Active 
Motif North America, Carlsbad, USA). Plasma cotinine (Bio-Quant, Inc, San Diego, USA), 
plasma nitrotyrosine (Cell Sciences, Canton, USA) and serum CRP (CRP; Geneway Biotech, 
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CA, USA) levels were measured using commercially available enzyme-linked 
immunosorbent assays. Liver and lung homogenates from all pigs were analyzed for EROD 
activity, as previously described (Weber et al., 2002).  
 
4.2.5.Bronchoalveolar lavage (BAL) fluid differential, total cell count and leukocyte 
elastase activity  
At the end of each experiment pigs were euthanized by an intravenous injection with 
pentobarbital sodium (Euthanol; 100 mg/kg). Bronchoalveolar lavage  was performed by 
infusing 40 ml of normal saline into the isolated trachea and lungs, with 20 ml of the lavage 
fluid retrieved in this process. First a hemocytometer was used to determine the total white 
blood cell count, then a cytospin preparation stained with Wright’s solution was used to 
determine the differential cell count in each BAL sample. Bronchoalveolar lavage  fluid 
leukocyte elastase activity was measured using a synthetic substrate i.e. N-succinyl-(ala)3-p-
nitroanilide (Sigma-Aldrich, ON, Canada) as previously described (Castillo et al., 1979).The 
activity of the enzyme was measured in units in which one unit of leukocyte elastase released 
one nanomole of p-nitrophenol per sec from BOC-L-alanine p-nitrophenyl ester at pH 6.5 at 
37 °C. 
 
4.2.6.Histological and morphometric analyses 
Following euthanasia, tissues from the heart, lung, liver as well as aorta, coronary and 
brachial arteries were collected and placed in 10% formalin. Tissues were paraffin-
embedded, serial 5 μm sections cut, stained with hematoxylin and eosin (H& E), and 
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mounted with Micromount (Surgipath, AB, Canada).  All tissues were evaluated for 
histopathological changes by a veterinary pathologist. For each artery, morphometric digital 
analyses were performed on 3 images captured from 3 different sections. Histological 
micrographs were taken using an Olympus BX41 microscope, attached to an Olympus DP71 
digital camera, and captured using DP controller software (Olympus Canada Inc., Markham, 
Canada).  Image Pro Plus7 was used to trace and measure the internal perimeter and wall 
thickness (WT) of each of the 3 images, and averages were then determined. From each 
perimeter the luminal diameter (LD) was calculated using the formula: diameter = P/ , and 
the ratio of LD to WT (LD/WT) was also determined. 
 
4.2.7.Statistical analysis 
Statistical analysis was performed using GraphPad Prism 5.03 (GraphPad Software, San 
Diego, CA, USA) or Systat 11 (Chicago, IL, USA). In order to correct for individual 
variation in baseline measurements that occurred among pigs, all subsequent measurements 
were normalized by dividing by their corresponding baseline values from the same pig. 
Differences among groups were analyzed by two-way analysis of variance with treatment 
and time as factors followed by Bonferroni posteriori tests. Terminal end points were 
analyzed by an unpaired t-test. A p-value < 0.05 was considered significant. All data were 
expressed as mean ± standard error of the mean (SEM).   
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4.3. Results 
4.3.1.Flow mediated dilation (FMD) validation  
Because FMD has not previously been reported in pigs, the time course of brachial artery 
dilation in 8 pigs was visualized before and after occlusion for four minutes. The diameter of 
the brachial artery increased gradually after cuff release until reaching a maximum at 90s 
post-occlusion (Figure 4.2). Based on this preliminary experiment, the 90s time-point was 
used for all subsequent FMD evaluations. Flow mediated dilation at this 90s time point was 
18.8 ± 1.0 % in normal, castrated male pigs. 
4.3.2.Flow mediated dilation (FMD), echocardiography, blood pressure, and blood 
gases evaluation 
Chamber conditions during ETS and sham exposures are summarized in Table 4.1. In 
general, the levels of CO and total particulates were higher during ETS exposures than sham 
exposures. Chamber O2 levels decreased after ETS exposure compared to sham exposure, but 
remained >21%. In contrast, CO2 levels remained below the detection limit (<0.5%) during 
both exposures. Serum cotinine levels after 4-weeks exposure were significantly higher in 
ETS-exposed compared to sham-exposed pigs (Table 4.1).  
In order to assess the effects of ETS on cardiovascular function in vivo, ultrasound and 
blood pressure assessments were performed weekly in pigs. A significant decrease in FMD 
was noted over time in both ETS and sham exposed pigs (p<0.05 for time factor in 2-way 
ANOVA; Figure 4.3). However, FMD was further decreased by ETS-exposure (p<0.05 for 
treatment factor), becoming significantly different from sham-exposed pigs in posteriori tests 
by Day 7 and continuing for the remainder of the experiment (Figure 4.3).
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Figure 4.2: A. Brachial artery diameter at baseline and 15, 30, 45, 60, 75, 90, 105 and 
120s post cuff release in normal, castrated male pigs (n=8). B. Flow mediated dilation 
(FMD) measured at baseline and at 15, 30, 45, 60, 75, 90, 105 and 120s post cuff release 
(n=8). Data are expressed as mean  standard error of the mean. *p<0.05 compared to 
pre-occlusion diameter in Bonferroni posteriori test after one-way analysis of variance. 
From these data 90s post cuff release was chosen for FMD evaluation because it was the 
time at which maximum relaxation was seen.  
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Table 4.1: Environmental tobacco smoke (ETS) exposure conditions and terminal plasma 
cotinine concentrations. Conditions in the exposure chamber were determined in preliminary 
experiments. Temperature and carbon monoxide (CO) were continuously monitored for 1 hr 
during ETS or sham exposure, and were expressed as a mean of 3 readings taken every 20 
minutes.  Particulates were sampled continuously during 1 hr sham or ETS exposure and are 
expressed as total particulate matter/hr.  A total of 11-12 cigarettes were burned during the 
daily ETS exposure. Blood samples, collected after exposure, on day 28 were used for 
plasma cotinine quantitation using an enzyme-linked immunosorbent assay. Data are 
expressed as mean ± standard error. *p<0.05 determined using an unpaired t-test with 
Welch’s correction.  
 
 Sham ETS 
Temperature  24ºC  23ºC 
CO (mean)  0  136 ppm 
Particulates 
O2 
CO2 
Plasma Cotinine 
 
 
 
 
30 μg/m3 
24% 
<0.5% 
2.1 ± 0.4 ng/ml 
 
 
 
 
110 μg/m3 
21% 
<0.5% 
51.6 ± 4.8 ng/ml* 
 
 
 38 
  
3
8
 
 
Figure 4.3: A. Changes in flow mediated dilation (FMD), normalized to pre-exposure 
values, over time after daily 1-hr environmental tobacco smoke (ETS) exposure or sham 
exposure for 28 day or B. after daily benzo[a]pyrene (BAP) or vehicle injection for 7 days. 
Data for each animal (n=4 per group for both experiments) are normalized to the baseline (or 
pre-exposure) response in the same individual. Data were analyzed by two way analysis of 
variance (ANOVA) with treatment and time as factors, and expressed as means  standard 
errors of the means (SEM). *p<0.05 compared to sham-exposure by Bonferroni posteriori 
test after two-way ANOVA. 
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Similar to that observed in the ETS exposure, FMD significantly decreased over time as 
the pigs grew (p<0.05 for time factor; Figure 4.3). However, in contrast to ETS, BAP 
exposure did not significantly impair FMD compared to vehicle injection at any time (Figure 
4.3).  
Left ventricular end-diastolic volume (EDV) and end-systolic volume (ESV), but not 
ejection fraction (EF) increased in a time-dependent manner as the pigs grew in both 
experiments (Figure 4.4, Table 4.2 and Table 4.3). More importantly, a significant overall 
increase in left ventricular EDV was found after ETS exposure compared to sham exposure 
(p<0.05 for treatment factor in 2-way ANOVA), but modified Bonferroni posteriori tests 
failed to detect any significant pair-wise effects (Figure 4.4). A trend pointing to a decrease 
in left ventricular ESV and an increase in EF was found after ETS exposure compared to 
sham exposure (Figures 4.4). In contrast, BAP injection had no significant effect on left 
ventricular EDV, ESV, or EF compared to vehicle injection (Figures 4.4). Heart and body 
weight were determined only at the termination of both experiments. No significant 
difference was found in heart weight, body weight or heart/body weight ratio between ETS 
exposed and sham exposed pigs, or BAP injected and vehicle injected pigs (Table 4.4). 
Blood pressure (systolic, diastolic, mean and pulse pressures) was not significantly altered 
over time or between ETS and sham exposed pigs (Table 4.5). Similarly no significant 
difference was found in blood pressure after BAP or vehicle injection (Table 4.6). Venous 
hemoglobin levels were altered by both ETS and BAP exposure, but in different manners 
(Figure 4.5, Table 4.7 and Table 4.8). Specifically, OxyHb tended to increase over time in 
sham-exposed pigs (Figure 4.5), but not in ETS-exposed pigs.
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Figure 4.4: Changes in left ventricular end diastolic volume (EDV; top panels), end-systolic 
volume (ESV; middle panels) and ejection fraction (EF; bottom panels) after daily 1-hr 
environmental tobacco smoke (ETS) or sham exposure for 28 days (A) or after daily 
benzo[a]pyrene (BAP) or vehicle injection for 7 days (B). Data for each animal (n=4 per 
group in both experiments) are normalized to the baseline (or pre-exposure) response in each 
individual and expressed as mean  standard error of the mean.  Effects of time and treatment 
were analyzed using two-way analysis of variance followed by modified Bonferroni 
posteriori tests, as appropriate. 
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Table 4.2: Absolute values obtained for end diastolic volume (EDV), end systolic volume 
(ESV), and ejection fraction (EF) determined over time after daily environmental tobacco 
smoke (ETS) or sham exposure for 28 days (n=4 pigs/group). Data are expressed as mean  
standard error of the mean. Absolute values are shown for qualitative evaluation only since 
statistical analyses were all performed on data normalized to pre-exposure values and results 
with significant changes are shown in corresponding figures. 
 
 ESV (ml) EDV (ml) EF% 
Sham ETS Sham ETS Sham ETS 
Baseline 
Day 1 
Day 7 
Day 14 
Day 21 
Day 28 
3.1  0.3 
3.7  0.5 
4.4  0.5 
5.6   0.6 
5.2  1.0 
5.5  0.5 
4.7  0.5 
4.4  1.3 
5.5  0.2 
6.8  0.5 
7.4  1.3 
5.7  0.6 
7.4  0.4 
11.1  1.2 
11.8  1.2  
14.2  2.0 
15.0  0.9 
16.3  1.7 
12.0  1.6 
14.4  1.9 
14.3   0.4 
16.5  0.4 
17.8  1.9 
16.6  0.6 
60  2 
68  3 
61  2 
59  2 
  59  34 
    65  4 
57  6 
66  1 
62  3 
59  3 
66  5 
    66  2 
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Table 4.3: Absolute values obtained for end diastolic volume (EDV), end systolic volume (ESV), and ejection fraction (EF) 
determined over time after daily injection with benzo[a]pyrene (BAP) or vehicle for 7days (n=4 pigs/group). Data are expressed as 
mean  standard error of the mean. Absolute values are shown for qualitative evaluation only since statistical analyses were all 
performed on data normalized to pre-exposure values and results with significant changes are shown in corresponding figures. 
 
 ESV (ml) EDV (ml) EF (%)  
 Vehicle BAP Vehicle BAP Vehicle BAP 
Baseline 
Day 1 
Day 7 
1.9  0.3 
2.5  0.2 
3.3  0.2 
2.0  0.2 
2.2  0.5 
3.1  0.4 
4.4  0.4 
5.9  0.2 
7.8  0.2 
4.4  0.2 
6.0  0.4 
8.7  0.6 
60  4 
58  4 
60  2 
54  5 
64  6 
63  6 
 
 
 
 
 44 
 
4
4
 
Table 4.4: Heart weight, body weight and heart / body weight ratio after daily environmental 
tobacco smoke (ETS) or sham exposure for 28 days (n=4 pigs/group), or benzo[a]pyrene 
(BAP) or vehicle injection for 7 days (n=4 pigs/group). Data are expressed as mean  
standard error of the mean. No significant differences were detected between ETS and sham-
exposed pigs as well as no differences between BAP- and vehicle-injected pigs using t-tests. 
 
 Heart weight 
(Kg) 
Body weight 
(Kg) 
 Heart / Body weight 
(%) 
     
Sham 
ETS 
 
Vehicle 
BAP 
0.209    0.04 
0.205  0.01 
 
0.071  0.002 
0.077 0.003 
31.75  6.3 
35.0  0.41 
 
12.94  0.51 
12.83  0.36 
 
 
 
 
 
0. 65  0.01 
0. 59  0. 03 
 
0. 55  0. 03 
0. 61  0. 04 
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Table 4.5: Absolute values for systolic, diastolic, mean arterial and pulse pressure (mmHg) over time after daily 
environmental tobacco smoke (ETS) or sham exposure for 28 days (n=4 pigs/group). Data are expressed as mean  standard 
error of the mean. Absolute values are shown for qualitative evaluation only since statistical analyses were all performed on 
data normalized to pre-exposure values and results with significant changes are shown in corresponding figures. 
 Systolic pressure         
(mm Hg) 
Diastolic pressure       
(mm Hg) 
Mean arterial 
pressure   (mm Hg) 
Pulse pressure                 
(mm Hg) 
Sham ETS Sham ETS Sham ETS Sham ETS 
Baseline 
Day 1 
Day 7 
Day 14 
Day 21 
Day 28 
   109  6 
    99  5 
   117  11 
   117  13 
   134  16 
   122  13 
124  20 
116  11 
147  14 
123  16 
118  13 
136  9 
49  4 
51  2 
54  4 
52  8 
54  4 
53  5 
55  6 
55  5 
59   6 
43  3 
59  12 
63  3 
70  4 
69  3 
76  3 
75  10 
82  7 
78  5 
79  11 
77  7 
90  8 
71  7 
80  12 
89  4 
60  7 
48  4 
63  7 
64  6 
80  15 
69  14 
69  14 
61  6 
88  10 
80  15 
59  5 
73  9 
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Table 4.6: Systolic, diastolic, mean arterial, and pulse pressure, over time after daily benzo[a]pyrene (BAP) or vehicle injection 
for 7 days (n=4 pigs/group). Data are expressed as mean  standard error of the mean. Absolute values are shown for qualitative 
evaluation only since statistical analyses were all performed on data normalized to pre-exposure values and results with significant 
changes are shown in corresponding figures. 
 
 Systolic pressure Diastolic pressure Mean arterial pressure Pulse pressure 
Vehicle BAP Vehicle BAP Vehicle BAP Vehicle BAP 
Baseline 
Day 1 
Day 7 
139  19 
107  11 
135  11 
115  8 
111  10 
111  3 
72  13 
61  7 
64  4 
57  1 
56  2 
47   2 
96  15 
78  8 
89  6 
78  3 
76  5 
69  2 
67  7 
47  6 
72  8 
58  9 
56  7 
64  2 
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 Figure 4.5: Changes in venous oxyhemoglobin (OxyHb; top panels) and methemoglobin 
(MetHb; bottom panels) after daily 1-hr environmental tobacco smoke (ETS) or sham 
exposure for 28 days (A) or after daily benzo[a]pyrene (BAP) or vehicle injection for 7 days 
(B). Data for each animal (n=4 per group in both experiments) are normalized to the baseline 
(or pre-exposure) response in the same individual and expressed as mean  standard error of 
the mean. Effects of time and treatment were examined using two-way analysis of variance 
followed by Bonferroni posteriori tests.   
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Table 4.7: Oxyhemoglobin (OxyHb) carboxyhemoglobin (CO-Hb), methemoglobin (MetHb) and total hemoglobin (TotalHb) in 
venous blood over time after daily environmental tobacco smoke (ETS) or sham exposure for 28 days (n=4 pigs/group). Data are 
expressed as means  standard errors of the means. Absolute values are shown for qualitative evaluation only since statistical 
analyses were performed on data normalized to pre-exposure values and results with significant changes are shown in 
corresponding figures. 
 
 OxyHb (%) CO-Hb (%) MetHb (%) TotalHb (mg/L) 
Sham ETS Sham ETS Sham ETS Sham ETS 
Baseline 
Day 1 
Day 7 
Day 14 
Day 21 
Day 28 
65.7  3.1 
79.2  6.6 
85.4  7.0 
85.2  6.5 
71.4  2.8 
85.2  7.6 
72.7  4.7 
85.0  6.4 
87.3  7.9 
75.1  7.4 
72.8  9.2 
73.9  7.5 
0.10  0.00 
0.15  0.05 
0.20  0.04 
0.15  0.03 
0.05  0.03 
0.10  0.04 
0.10  0.00 
0.65  0.41 
0.45  0.26 
0.23  0.05 
0.13  0.06 
0.05  0.03 
2.4  0.1 
2.0  0.3 
1.8  0.2 
1.9  0.1 
2.7  0.2 
2.1  0.4 
2.4  0.1 
1.1  0.2 
0.8  0.1 
1.5  0.5 
1.4  0.4 
2.7  0.1 
113  4 
108  2 
108  1 
108  5 
109  4 
118  7 
102  7 
95  4 
101   1 
106  5 
103  3 
106  8 
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Table 4.8: Oxyhemoglobin (OxyHb) carboxyhemoglobin (CO-Hb), methemoglobin (MetHb) and total hemoglobin (TotalHb) in 
venous blood over time after daily benzo[a]pyrene (BAP) or vehicle injection for 7 days (n=4 pigs/group). Data are expressed as 
mean  standard error of the mean. Absolute values are shown for qualitative evaluation only since statistical analyses were  
performed on data normalized to pre-exposure values and results with significant changes are shown in corresponding figures. 
 
 
 
 
 OxyHb (%) CO-Hb (%) MetHb (%) TotalHb (mg/L) 
 Vehicle BAP Vehicle BAP Vehicle BAP Vehicle BAP 
Baseline 
Day 1 
Day 7 
86.6  5.3 
82.8  10.4 
85.2  5.4 
75.0  6.5 
73.0  3.4 
71.4  7.7 
0.10  0.00 
0.15  0.03 
0.18  0.05 
0.10  0.00 
0.10  0.00 
0.15  0.03 
2.3  0.2 
2.0  0.1 
2.0  0.2 
2.5  0.1 
2.8  0.3 
2.9  0.3 
97  10 
97  10 
71  27 
120  8 
84  21 
66   15 
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This led to an overall decreased level of venous OxyHb in ETS-exposed compared to sham-
exposed pigs (p<0.05 for treatment factor in 2-way ANOVA), but posteriori tests failed to 
detect specific time points where differences were significant (Figure 4.5). In contrast, BAP 
injection had no significant effect on venous OxyHb levels at any time (Figure 4.5; Table 
5.8). Venous MetHb was significantly decreased in the earlier time-points of ETS exposure 
compared to sham-exposure (p<0.05 for both time and treatment factors in 2-way ANOVA), 
but then returned to pre-exposure levels by day 28 of this experiment (Figure 4.5). This 
biphasic response of MetHb in the ETS-exposed pigs created a significant interaction 
between the time and treatment variables (Figure 4.5). In contrast, BAP injection caused a 
significant increase in MetHb levels compared to vehicle-injected pigs without any 
interaction between the factors in ANOVA analyses (Figure 4.5). Carboxyhemoglobin and 
TotalHb were not significantly altered by ETS exposure (Table 4.7) or BAP injection (Tables 
4.8) compared to their respective controls.  
 
4.3.3.Plasma nitrate/nitrite, nitrotyrosine, C-reactive protein (CRP), and ethoxyresorufin-
o-deethylase (EROD) activity 
Overall, serum nitrate/nitrite levels (an indicator of NO production) were highly variable 
and no significant changes were observed after either ETS or BAP exposure compared to 
their corresponding control groups (Table 4.9). However, BAP injection caused a significant 
increase in nitrotyrosine (an indicator of NO inactivation by superoxide free radical via 
peroxynitrite formation) compared the vehicle-injected group by day 7 (Figure 4.6). An 
increase of similar magnitude in nitrotyrosine was also observed at the end of 28 days of ETS 
exposure compared to sham exposure, but was not quite statistically significant (Figure 4.6). 
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C-reactive protein (an acute phase inflammatory protein) was significantly elevated after 
both ETS and BAP exposure compared to their respective controls (Figures 4.7). Inhalation 
exposure to ETS caused a significant increase in lung, but not liver EROD activity compared 
to sham-exposed pigs (Figure 4.8). In contrast, intravenous BAP injection caused the 
opposite result, with a significant increase in liver, but not lung EROD activity compared to 
vehicle injection (Figure 4.8).  
4.3.4.Bronchoalveolar lavage (BAL) fluid total white blood cell count, BAL 
differential cell count, BAL leukocyte elastase activity and tissue histology   
The total WBC count in BAL fluid was significantly increased after ETS (Figure 4.9), but 
not after BAP exposure compared to their respective controls (Figure 4.9). Macrophages 
were the only inflammatory cell type found within BAL fluid from both ETS and sham-
exposed pigs. A subjective evaluation of lung sections showed an increase in intraalveolar 
macrophages in  ETS-exposed pigs compared to sham-exposed pigs (Figure. 4.10). No 
significant difference was found in BAL fluid leukocyte elastase concentration after either 
ETS or BAP exposure compared to their respective controls (Table 4.10). No 
histopathological evidence of lung emphysema was found in any of the samples from these 
experiments (Figure 4.10). Furthermore, no histopathological lesions were detected in any 
other tissue that was evaluated; liver, heart or arteries (Figure 4.11). Finally, there was no 
significant difference in arterial wall thickness or arterial diameter (evaluated as luminal 
diameter, wall thickness or a ratio of the two) in aorta, brachial artery or coronary artery after 
ETS or BAP exposure compared to their respective control tissues (Table 4.11). 
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Table 4.9: Total serum nitrate/nitrite levels over time after daily environmental tobacco 
smoke (ETS) or sham exposure for 28 days, and benzo[a]pyrene or vehicle injection for 
7days. Data are expressed as mean  standard error of the mean and n=4 pigs/group for both 
experiments. ND: Not determined. No statistically significant differences were detected using 
separate two-way analyses of variances for each experiment (time and treatment as factors). 
 
                                    Total nitrate/nitrite (µM) 
 Sham ETS Vehicle BAP 
Baseline 
Day 1 
Day 7 
Day28 
4.9  2.6 
5.2  1.2 
ND 
1.4  0.7 
4.6  0.7 
4.3  1.6 
ND 
0.9  0.2 
7.7  0.8 
5.7  1.7 
1.7  0.6 
------ 
9.5  2.8 
7.9  1.9 
5.4  3.4 
------ 
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Figure 4.6: A. Serum nitrotyrosine levels after 28 days of environmental tobacco smoke 
(ETS) or sham exposure or B. after 7 days of benzo[a]pyrene (BAP) or vehicle injection. 
Data are expressed as mean  standard error of the mean and n=4/group in both experiments. 
*p < 0.05 in unpaired t-test with Welch’s correction.  
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Figure 4.7: A. Serum C-reactive protein levels after 28 days of environmental tobacco 
smoke (ETS) or sham exposure or B. after 7 days of benzo[a]pyrene (BAP) or vehicle 
injection. Data are expressed as mean  standard error of the mean and n=4/group in both 
experiments. *p < 0.05 in unpaired t-test with Welch’s correction. 
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Figure 4.8: Ethoxyresorufin-o-deethylase (EROD) activity in liver (A,B) and lung (C,D) 
microsomes prepared from pigs after 28 days of environmental tobacco smoke (ETS) or 
sham exposure (A,C) as well as after 7 days of benzo[a]pyrene (BAP) or vehicle injection 
(B,D). Data are expressed as mean  standard error of the mean and n=4 pigs/group for both 
experiments.  *p < 0.05 in unpaired t-test with Welch’s correction. 
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Figure 4.9: A. Total white blood cell (WBC) count in bronchoalveolar lavage (BAL) fluid 
collected from pigs after 28 days of environmental tobacco smoke (ETS) or sham exposure 
or B. after 7 days of benzo[a]pyrene (BAP) or vehicle injection. Data are expressed as mean 
 standard error of the mean and n=4 pigs/group in both experiments. *p < 0.05 in unpaired 
t-test with Welch’s correction.  
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Table 4.10: Leukocyte elastase concentration in bronchoalveolar lavage (BAL) fluid 
collected from pigs after 28 days of environmental tobacco smoke (ETS) or sham exposure, 
or after benzo[a]pyrene (BAP) or vehicle injection for 7days. Data are analyzed by an 
unpaired t test with Welch’s correction and expressed as mean  standard error of the mean. 
U: standard Unit of elastase activity. 
 
Treatment type Leukocyte elastase (U) p-value  
 
 
 
 
4.4.  
Sham 
ETS 
 
Vehicle 
BAP 
0.36  0.06 
0.65  0.16 
 
0.29 0.05 
0.43  0.08 
0.1350 
 
 
0.1962 
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                        A                                                                            B 
                        
 
Figure 4.10: Representative histological micrographs of hematoxylin/eosin-stained lung 
tissue collected from pigs after 28 days of sham (A) or environmental tobacco smoke (ETS) 
(B) or exposure. Qualitative histological assessment of alveoli revealed an increase in 
intraalveolar macrophages after ETS exposure (arrows). Bar = 100 µm.  
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Figure 4.11: Histological micrographs of hematoxylin/eosin-stained liver, heart and 
coronary artery, brachial artery and aorta collected from pigs after 28 days of sham 
(A,C,E,G) or environmental tobacco smoke exposure (B,D,F,H). No pathological 
abnormalities were noted in any of these tissues.Bar = 200 µm (A,B). Bar = 2 mm (C-H).  
  
 
6
1 
Table 4.11: Measures of wall thickness and diameter of arteries after 28 days environmental tobacco smoke (ETS) or sham-
exposure as well as 7 days benzo[a]pyrene (BAP) or vehicle injection. Luminal diameter (LD), wall thickness (WT) and luminal 
diameter/wall thickness (LD/WT) of aorta, brachial and coronary arteries were determined by digital morphometric analyses of 
hematoxylin/eosin-stained sections. Data are expressed as mean  standard error of the mean. No significant differences were 
detected using unpaired t-tests with Welch’s correction.  
 
                          Coronary artery             Brachial artery                   Aorta 
 LD WT LD/WT LD WT    LD/WT LD WT LD/WT 
Sham  
ETS  
 
Vehicle 
BAP  
1.4  0.06 
1.4  0.12 
 
1.2  0.09 
1.32  0.12 
0.20.02 
0.20.04 
 
0.30.03 
0.30.02 
6.20.5 
6.20.4 
 
4.70.2 
4.60.4 
2.50.10 
2.40.20 
 
0.20.03 
0.20.03 
0.40.02 
0.40.02 
 
0.20.04 
0.30.03 
6.50.3 
6.90.8 
 
9.01.4 
8.71.4 
5.50.3 
5.70.3 
 
3.30.3 
3.50.3 
1.10.1 
1.10.1 
 
0.60.1 
0.50.1 
5.30.6 
5.30.3 
 
5.70.6 
6.70.5 
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4.5. Discussion 
The most important finding of this study is that exposure to daily 1-hr ETS impaired 
vascular endothelial function as early as 7 days with progressive impairment continuing until 
the end of the experiment at 28 days. However, this effect was not mimicked by intravenous 
administration of a high dose of the tobacco smoke constituent, BAP. Similarly, ETS 
exposure, but not BAP injection, altered cardiac function by increasing EDV with a trend to 
increasing EF and decreasing ESV, which suggests a stimulatory effect on heart function. In 
contrast, both ETS exposure and BAP injection resulted in systemic inflammation, increased 
EROD activity, increased oxidative stress and increased biological inactivation of NO which 
should have produced similar levels of impairment in endothelial function. However, since 
endothelial function was only impaired after ETS, but not BAP exposure, the connection 
between NO activity and endothelial function differed in the two experiments in the current 
study. Finally, ETS exposure, but not BAP injection, caused lung inflammation and increased 
the total WBC count within BAL fluid without evidence of emphysema or changes in 
leukocyte elastase levels. Taken together, these results suggest either that pulmonary 
inflammatory responses or pulmonary increases in EROD activity may be more important 
links to endothelial dysfunction than systemic inflammation and NO bioactivity.  
We show for the first time the feasibility of using FMD in conscious healthy pigs to 
assess endothelial function. Flow mediated dilation use has been previously validated in 
conscious dogs (Puglia et al., 2006) and in humans (Harris et al., 2010). However, a pig 
model was used in this thesis because pigs are more similar to human beings in terms of diet, 
anatomy, aortic size and progression of CVD than rodents or dogs (Hasenkam et al., 1988). 
The peak dilatory response found in the current study at 90s matches what is routinely used 
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in humans. However, the magnitude of the FMD response we determined in pigs (18%) is 
slightly higher than that reported in healthy dogs (7-10%) or healthy humans (10-12%). The 
reason for this difference in FMD magnitude is unknown, but could be due either to species 
differences or to the fact that FMD measurements were performed in pigs sedated with 
azaperone which is known to have vasodilatory properties. However, it has been shown in 
humans that if arteries are pre-dilated due to a variety of other interfering stimuli (e.g. heat, 
exercise), it tends to reduce their ability to further dilate and reduces, not enhances, FMD 
responses (Harris et al., 2010). One other difference between this study and others was the 
use of cross sectional rather than longitudinal ultrasound views of the brachial artery to 
evaluate FMD. There is debate within the human literature about which method is superior 
(Harris et al., 2010) and at least one study claims cross-sectional views are superior to the 
longitudinal approach (Kao et al., 2003). The decrease in FMD noted over time in both sham 
and ETS-exposed pigs suggests that FMD decreased with age and growth.  A similar finding 
has been reported in rats, where a more invasive version of FMD was performed on the 
femoral artery (Heiss et al., 2008). Flow mediated dilation was lower in 20-24 week old rats 
(16.0%) compared to 9-10 week old rats (12.6%) in this previous study.  Therefore, based on 
our ability to detect similar age-related changes to that reported previously plus the 
reproducibility of FMD values in different groups of control pigs within this thesis, we are 
confident that the cross-sectional FMD method used in azaperone-sedated pigs is robust and 
reliable as a test of endothelial function. 
Similar to what was found in human beings (Peluffo et al., 2009b), the exposure of pigs 
to ETS results in impairment of FMD. In contrast to ETS, the tobacco smoke component 
BAP did not cause FMD impairment. This suggests that BAP by itself is not responsible for 
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mediating FMD impairment. Although BAP was not administered by inhalation for safety 
reasons, the administered intravenous dose was several orders of magnitude greater than the 
amount of BAP found in cigarette smoke (Ding et al., 2008). Several studies have reported 
that brachial artery FMD is completely NO dependent in humans (Green, 2005). Serum 
nitrate/nitrite levels have been used as surrogate marker for eNOS activity and NO 
production. It has been shown that cigarette smoke decreases eNOS activity in a dose-
dependent manner in human beings (Zhang et al., 2006). Moreover, free radicals within 
cigarette smoke react with NO to produce peroxynitrite, thereby decreasing NO 
bioavailability (Zhang et al., 2006). In support of this, the current study found elevated serum 
nitrotyrosine (a by-product of peroxynitrite) levels after ETS exposure. However, 
nitrotyrosine was also increased after BAP injection, suggesting a similar decrease in NO 
bioavailability, but yet FMD was unchanged in this experiment. The lack of change in NO 
production accompanied by increased nitrotyrosine after chronic exposure to either ETS or 
BAP exposure agrees with recent studies in rats from this laboratory (Gentner and Weber, 
2010b). Possibly explaining the discrepancy in FMD responses between the current ETS and 
BAP experiments in pig, other investigators have shown that FMD is maintained in eNOS 
knockout mice (Huang et al., 2001). Additionally, in human beings the administration of N-
G-monomethyl-L-arginine (L-NMMA), an eNOS inhibitor, does not blunt FMD response in 
radial artery subjected to 15 minutes of ischemia (Mullen et al., 2001). In all these cases, it 
has been suggested that endothelium-derived hyperpolarizing factor (EDHF) compensates 
where NO bioavailability is impaired. A possible explanation for the results of the current 
study is that although NO bioavailability was impaired after both ETS and BAP exposure, 
FMD remained NO-dependent after ETS exposure and thus was impaired. In contrast, the 
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FMD response may have switched from an NO-dependent to an EDHF-mediated dilation 
after BAP exposure; thereby maintaining the FMD response despite decreased NO 
bioavailability. The difference in time of exposure (7 days versus 28 days) is clearly an 
important difference between the BAP and ETS experiments. Therefore, the relative 
contribution of NO versus EDHF in the FMD response needs to be investigated more 
specifically in future time-course experiments with ETS and BAP. 
Endothelial dysfunction may have a negative impact on cardiac function. By causing 
arterial stiffness, this leads to increased peripheral resistance, increased afterload and 
hypertension. Thus, chronic endothelial dysfunction can result in left ventricular hypertrophy 
and subsequent coronary insufficiency (Verma and Solomon, 2009). Additionally, cigarette 
smoke exposure enhances the progression of hypertension-induced myocardial hypertrophy 
in spontaneously hypertensive rats (Meurrens et al., 2007). Eventually, hypertrophy 
progresses to contractile dysfunction and heart failure. A few investigations have found that 
older male
 
smokers have higher systolic blood pressure than nonsmokers consistent with 
increased arterial stiffness (Primatesta et al., 2001), while others, paradoxically, found lower 
blood pressure among smokers compared to nonsmokers (Berglund and Wilhelmsen, 1975). 
Recent studies from this laboratory have shown that acute ETS exposure has no effect or 
decreases blood pressure in rats, detected using blood pressure telemetry techniques (Gentner 
and Weber, 2010c). In contrast, chronic ETS and BAP exposure both caused an overall 
increase in diastolic pressure and arterial stiffness plus a failure of both systolic and diastolic 
pressures to dip during periods of sleep (Gentner and Weber, 2010a). In the current study, 
FMD was impaired after ETS exposure, but no structural or histopathological changes 
occurred and blood pressure remained unchanged. This may indicate that the impairment of 
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FMD was not yet large enough to cause a detectable change in systemic blood pressure, but 
longer ETS exposures than 28 days may well have led to detectable changes in blood 
pressure. Furthermore, the sensitivity of the method used for blood pressure evaluation in this 
study (oscillometric blood pressure cuff) and the small sample size could also be the cause of 
no change in blood pressure. The use of telemetry is now considered the gold standard 
method for blood pressure monitoring in rodent experiments, particularly if the expected 
treatment effect is <30 mmHg (Kurtz et al., 2005; Pickering et al., 2005), but this method 
requires surgery and is not routine in larger animals such as the pig. In the current study, the 
observed increase in EDV and ESV over time in all pigs regardless of treatment, in the 
absence of structural or pathological changes, is related to growth. Since we were able to 
detect consistent growth-related changes in cardiac function, we are confident of our ability 
to have detected treatment effects on cardiac function. Therefore, the lack of effect of 7-day 
BAP exposure on cardiac function seems real and suggests other components of ETS are 
responsible for the observed alterations in function or that 7 days exposure was insufficient to 
produce an effect. In support of the former possibility, acute nicotine (a constituent of 
tobacco smoke) administration is known to increase heart rate and ejection fraction in 
humans (Benowitz and Gourlay, 1997) and dogs (Ilebekk and Lekven, 1974). Therefore, the 
increased EDV, increased EF and decreased ESV observed after ETS exposure in the current 
study is most likely due to the acute effects of nicotine.  
Hemoglobin levels are reported to be 0.3-4% higher in smoker compared to nonsmokers 
(Andrews and Tingen, 2006), possibly due to effects of chronic hypoxia. In this study, no 
significant difference in TotalHb or CO-Hb levels were found after ETS exposure despite 
slightly lower levels of O2 and high levels of CO in the exposure chamber. This seems to 
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indicate that CO is not responsible for the observed FMD impairment. Although the 
significant decrease in OxyHb after ETS exposure observed in the current study may relate to 
the lower O2 in the exposure chamber, similar decreases in OxyHb have also been reported in 
human epidemiologic studies (Van Tiel et al., 2002). Therefore, the decreased hemoglobin-
oxygen content may instead be a common effect of tobacco smoke exposure. By definition, 
MetHb is the oxidized form of iron in hemoglobin and levels increase in the presence of 
oxidative stress caused by smoke exposure (Wright et al., 1999). Thus, the significant 
increase in MetHb levels after BAP exposure observed in the current study is consistent with 
the increased oxidative stress suggested by higher nitrotyrosine. In contrast, ETS caused a 
paradoxical decrease in MetHb levels, but yet nitrotyrosine was increased in the current study. 
Possibly related is the observation in a previous study that MetHb increased after oral BAP 
exposure in CYP1A1 knockout mice, but decreased in wild-type mice (Uno et al., 2004). 
Thus, the differential expression of CYP1A1 between the ETS and BAP experiments in the 
current study may have led to opposite MetHb effects. 
The metabolism of BAP is mediated through the enzyme CYP1A1 which converts BAP 
to more toxic metabolites i.e. 9,10-epoxy-7,8-dihydrodiol and quinone metabolites (Wislocki 
et al., 1976). These metabolite are implicated in cancer development and oxidative stress, 
respectively (Wislocki et al., 1976). Similar to previous reports in humans (Anttila et al., 
2001), the inhalation exposure of pigs to ETS resulted in CYP1A1 induction within the lung. 
Since the lungs are the point of entry for these ETS exposures, it seems logical that all Ahr 
agonists within ETS were metabolized within the lungs without escaping into the systemic 
circulation since liver CYP1A1 activity was unchanged. In contrast, the induction of 
CYP1A1 in the liver, but not the lung, after intravenous BAP exposure is expected after 
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intravenous injection (Wislocki et al., 1976) since the liver would be the major site of 
detoxification for systemically absorbed Ahr agonists. The increased CYP1A1 activity within 
both tissues would have produced a large amount of reactive PAH metabolites, increasing 
oxidative stress within that tissue. However, it is unclear whether these metabolites and 
subsequent ROS would have lasted long enough to escape the tissue. The increased level of 
plasma nitrotyrosine after both BAP and ETS exposure in the current experiment suggests 
that some of these molecules did escape the liver and lungs, respectively, to exert effects 
within the systemic circulation. However, since FMD impairment was observed only after 
ETS, not BAP exposure, a more indirect effect, perhaps involving the lung may be more 
physiologically important. 
Alternatively, increased systemic oxidative stress could be caused by systemic 
inflammation (Taddei et al., 2006). C-reactive protein is a marker for systemic inflammation 
produced by the liver and is elevated in smokers (Antoniades et al., 2004; May and Wang, 
2007). Small increases in serum CRP are also used as a predictor for CVD such as coronary 
heart disease (Antoniades et al., 2004; May and Wang, 2007). The finding that ETS caused 
an increase in CRP serum levels is consistent with other reports indicating that ETS causes 
low-level systemic inflammation (Gan et al., 2005). The increase in CRP after BAP exposure 
indicates not only that BAP can also cause systemic inflammation, but also suggests that 
BAP and related compounds may be the component within cigarette smoke that is 
responsible for CRP elevation. Furthermore, increased WBC count observed in the current 
study in BAL fluid from pigs exposed to ETS indicates that ETS causes lung inflammation. 
The majority of inflammatory cells noted on BAL fluid smears and on histological lung 
section were macrophages. These cells are not only capable of generating ROS, but can also 
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release inflammatory cytokines that cause endothelial dysfunction (Fujii et al., 2002). Lung 
inflammation was not evident after BAP exposure in the current study because BAP was not 
administered by inhalation; therefore lung-specific changes were not expected. Of all the 
end-points examined in the current study, FMD impairment and lung inflammation are two 
prominent changes that occurred with ETS, but not BAP exposure. Thus, although we cannot 
say for sure whether ETS-induced lung inflammation is related to FMD impairment, it seems 
a likely candidate that needs to be explored in future studies.  
People with COPD have impaired lung function and are at increased risk of developing 
CVD (MacNee et al., 2008). This association between COPD and CVD could be related to 
common risk factors such as smoking (Malerba and Romanelli, 2009). Smoking not only 
causes lung inflammation and oxidative systemic stress, but also results in increased release 
of proteolytic enzymes within the airspaces leading to emphysema (MacNee et al., 2008). In 
the current study, likely due to the relatively short duration of exposures, no significant 
difference was found in BAL fluid leukocyte elastase concentration after either ETS 
exposure or BAP injection. Therefore, although lung inflammation was evident in the current 
study after 28 days of ETS exposure, it had not yet progressed to more permanent structural 
changes within the lungs.  
In summary, this study provides a good model utilizing FMD to study changes in 
endothelial function due to known cardiovascular risk factors such as ETS exposure. The 
critical observations of the current study were that ETS exposure caused impaired endothelial 
function with evidence of systemic and lung inflammation, increased lung CYP1A1 activity 
and oxidative stress. In contrast, BAP failed to alter endothelial function despite systemic 
inflammation and increased oxidative stress. Taken together, these results suggest either that 
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pulmonary inflammatory responses or pulmonary increases in CYP1A1 activity may be more 
important links to endothelial dysfunction than systemic inflammation and NO bioactivity. 
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5. Failure of resveratrol to ameliorate pulmonary inflammation, 
CYP1A1 activity, and endothelial dysfunction after 
environmental tobacco smoke exposure in juvenile pigs 
 
5.1. Introduction 
The adverse health effects of cigarette smoke involve almost every organ system in 
smokers (Alberg, 2008; Bartal, 2001). However, cardiovascular and respiratory effects are 
most prevalent, and includ diseases such as atherosclerosis, coronary artery disease, asthma, 
and COPD (Armani et al., 2009; Bhalla et al., 2009).  Exposure to second-hand tobacco 
smoke, also referred to as ETS, poses an increased risk for many of these same diseases. In 
fact, smoking with ETS exposure is considered the number one preventable risk factor 
contributing to CVD.  
Endothelial cells play a key role in the regulation of vascular tone and impairment of 
normal endothelial function is thought to be an early step in the development of all CVD, 
including that in smokers (Luscher, 1994). Therefore, assessing endothelial function has 
become increasingly important as a prognostic clinical tool and a method used in mechanistic 
investigations of cardiovascular pathophysiology (Harris et al., 2010). Flow mediated 
dilation is an endothelium-dependent ultrasound technique which measures the ability of 
conduit arteries to relax and expand in response to a shear stress and hypoxia. The extent of 
flow mediated dilation has been used as an early predictor for CVD (Martin, 2009) and is 
thought to be mediated largely by NO. Flow mediated dilation has been shown to be 
impaired in smokers, which might be related to an oxidative stress-mediated decrease in NO 
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bioavailability (Celermajer et al., 1996; Karatzi et al., 2007; Peluffo et al., 2009b). However, 
the effect of ETS on endothelial function is less clearly established. 
Cigarette smoke-induced oxidative stress is a major pathway contributing to the 
development of CVD (Minicucci et al., 2009; Vardavas and Panagiotakos, 2009). Of the 
more than 4000 compounds found in cigarette smoke, numerous classes of toxic chemicals 
have been implicated in causing this increased oxidative stress including: reactive 
metabolites of PAHs via cytochrome P450 1A1 (CYP1A1) activity (Borgerding and Klus, 
2005; Ding et al., 2008), carbon monoxide (CO) (Thom et al., 1997) and nicotine (Rahman 
and Laher, 2007). With increased oxidative stress, peroxynitrite is produced as a result of the 
interaction between superoxide anion and NO (Ischiropoulos and al-Mehdi, 1995; van der 
Vliet et al., 1995) which leads to reduced NO bioavailability and impaired vasodilation 
(Peluffo et al., 2009b). Peroxynitrite formation can be indirectly monitored by measurement 
of serum 3-nitrotyrosine levels, a by-product of peroxynitrite’s interaction with proteins. 
Additionally, epidemiologic studies have shown that cigarette smokers have higher levels of 
CRP in their serum compared to non smokers (Antoniades et al., 2004; Hanyu et al., 2009). 
C-reactive protein is an acute phase protein elevated during systemic inflammation 
(Antoniades et al., 2004). Individuals with high CRP serum levels exhibit increased oxidative 
stress (van der Vaart et al., 2004) and are at increased risk of developing CVDs (May and 
Wang, 2007). Previous studies have also indicated that ETS exposure causes lung 
inflammation (see Chapter 2 of this thesis; Gentner and Weber, 2010c). Not only is this 
increased lung inflammation linked to lung dysfunction (Chan-Yeung and Dimich-Ward, 
2003; Salvi and Barnes, 2009) and eventual development of emphysema (Sharafkhaneh et 
al., 2008), but it may also serve as a source of systemic inflammatory mediators that 
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increases systemic oxidative stress. Therefore, the mechanisms by which ETS increases 
oxidative stress are not clear, but may involve direct or indirect actions of toxic smoke 
constituents as well as inflammatory reactions. 
Natural antioxidants within fruits and vegetables are receiving increasing attention in 
recent years, because of their putative protective role in CVDs, cancer, and inflammation 
(Kode et al., 2008). Resveratrol is a polyphenolic compound, found in the skin and seeds of 
red grapes, with antioxidant (Kawada et al., 1998), anti-inflammatory (Donnelly et al., 
2004), and anti-carcinogenic properties (ElAttar and Virji, 1999). In the early nineties, an 
epidemiologic study reported that the low mortality among the French population from 
coronary heart disease compared to North Americans, despite much higher smoking rates, 
was related to the consumption of red wine (Renaud and de Lorgeril, 1992). The cardio-
protective property of red wine has been attributed to RES. Additionally, it has been shown 
that RES attenuates cigarette smoke-induced oxidative stress and proinflammatory 
phenotypic alterations within endothelial cells (Csiszar et al., 2008).  
We hypothesized that chronic exposure to ETS would result in lung and systemic 
inflammation which in turn would result in endothelial dysfunction, impaired FMD, 
increased blood pressure, impaired left ventricular function and increased broncho-alveolar 
lavage elastase associated with emphysema. We also hypothesized that these effects could be 
abolished by RES treatment. In order to evaluate this hypothesis we randomized 16 castrated 
male pigs into 4 groups in a 2x2 factorial study design i.e. sham, RES, ETS, and RES+ETS 
for 14 days. A fourteen day exposure was chosen based on a previous time-course study from 
this laboratory showing consistent impairments in FMD after daily ETS exposure by this 
time-point (see Chapter 2 of this thesis). Flow mediated dilation, left ventricular end-systolic 
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volume (ESV), end-diastolic volume (EDV), ejection fraction (EF), mean arterial pressure, 
systolic pressure, diastolic pressure, CO-Hb, oxyhemoglobin (OxyHb), MetHb, 
totalhemoglobin (TotalHb), pO2, pCO2, serum nitrate/nitrite (NOx), nitrotyrosine and CRP, 
and liver CYP1A1 and lung CYP1A1 were measured. Total and differential cell counts, and 
neutrophil elastase levels in bronchalveolar lavage (BAL) fluid were performed at Day 14. 
Histological and morphometric analyses were performed on the abdominal aorta, brachial, 
and coronary arteries as well as histopathological evaluation of the lung, liver and heart.    
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5.2. Materials and methods 
5.2.1.Animals and experimental design 
All protocols were in accordance with the Canadian Council on Animal Care guidelines 
and were approved by the Animal Care and Use Council at the University of Saskatchewan. 
Sixteen castrated male pigs (10-12 kg) were obtained from Prairie Swine Center (Saskatoon, 
SK) and randomized into 4 groups i.e. sham, RES, ETS and RES+ETS (4 pigs/group).  The 
pigs were group-housed with each treatment group kept in separate pens under a 12 hr 
dark/12 hr light cycle. The pigs were fed normal pig starter chow (Federated Co-Operatives 
Ltd, Saskatoon, Canada) and water ad libitum except during exposure, injection or 
cardiovascular assessment.  
 
5.2.2.Environmental tobacco smoke (ETS) and resveratrol (RES) exposure 
A single cigarette manual smoking machine from CH Technologies Inc (Westwod, USA) 
was used to generate ETS (mainstream plus side stream smoke). The machine was adjusted 
to a rate of 3 puffs /minute with 57 ml/puff of 2 second duration. The ETS, mixed with 
unfiltered indoor air, was then pumped into a 500 gallon polyethylene plastic water tank 
modified to include inflow and out flow ports and a sealed, removable plexiglass door in 
which unsedated, unrestrained pigs (n=4 per group) were exposed. Pumps controlling inflow 
were set at 6 L/min. A total of 12 cigarettes (Canadian Classics, Rothmans, Benson & 
Hedges, Canada) were burned over the span of 1 hr every day for 14 days.  Sham exposed 
and RES+sham-treated pigs (n=4 pigs/exposure) were placed in the same chamber for the 
same duration but with unlit cigarette attached to the smoking machine. The total particulate 
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count in the chamber was assessed for the cigarette exposed and control pigs using a SKC 
constant airflow pump (Universal 224-PCXR, Eighty Four, PA) fitted with pre-weighed 
mixed cellulose ester filter (0.08 μm, SKC Inc., Eighty Four, PA).  Total particulates were 
sampled continuously for one hour at 2L/min. Carbon monoxide levels were also monitored 
in both groups using a T40 Rattler CO monitor (Industrial scientific, Corp, Oakdale, USA) 
placed inside the chamber for the duration of the exposure. The air levels of O2 / CO2 within 
the chamber were measured using a Criticare Poet IQ multiparameter gas monitor (Criticare 
Systems, Inc., Waukesha, USA). Pigs in the RES+sham and RES+ETS groups received a 
daily dose of RES (5mg/kg) (MegaRES, Danbury, CT, USA) which was given orally within 
a gelatin capsule inserted into their pharynx for 14 days. 
 
5.2.3.Flow mediated dilation (FMD), echocardiography, blood pressure, and blood 
gas evaluation 
Immediately after each sham or ETS exposure, pigs were sedated by receiving an 
intramuscular injection of azaperone (2.2 mg/kg, Stresnil™ Merial Inc, Canada) and body 
temperature was measured using a rectal thermometer. Pigs were placed on left lateral 
recumbency.  The left brachial artery was visualized using a SonoSite 180 Plus ultrasound 
unit with a 5.0 MHz linear array transducer (SonoSite Canada Inc., Markham, Ont., Canada). 
The probe was placed on the medial aspect of the distal third of the left radius, approximately 
10 centimeters from the axilla. The blood pressure cuff was applied directly distal to the 
ultrasound area. The brachial artery was visualized at baseline (unoccluded). The blood 
pressure cuff was then inflated to 30 mm Hg above systolic pressure for 4 minutes. 
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Following cuff release the brachial artery was visualized for 150 s. All ultrasound views were 
recorded using a digital video camera for the duration of the ultrasound time and uploaded to 
a computer. Single digital images of the brachial artery were created at baseline and 90 s, 
after cuff release using Adobe Premiere Elements (Adobe Inc., San Jose, CA, USA). The 
perimeter (P) of the brachial artery at each time point was traced and measured using Image-
Pro Plus (Media Cybernetics Inc., Bethesda, MD, USA) and converted to a diameter using 
the formula: diameter = P/ . The diameter of the brachial artery at baseline and 90s were 
used to calculate FMD. All measurements of digital ultrasound images were performed 
blinded. The flow mediated dilation was calculated using the formula: 
% FMD = (90s post-release diameter) – (baseline diameter) x 100% 
                                       (baseline diameter) 
The left ventricular end-systolic volume (ESV) and end-diastolic volume (EDV) were 
measured using an HP SONOS 100CF ultrasound machine.  A 5.0 MHz cardiac transducer 
was used in the right parasternal long-axis view to visualize the left ventricular outflow tract 
during systole and diastole. For each end point two measurements were taken and then 
averaged. The ejection fraction (EF) was calculated using the formula: 
 EF = [(EDV – ESV) / (EDV)] × 100% 
After vascular and cardiac ultrasound, a Memo Diagnostic High Definition Oscillometer 
(S + B medVET, Markham, Ont. Canada) was placed on the distal end of the right hind limb 
to measure systolic pressure, diastolic pressure, mean arterial pressure (MAP) and heart rate. 
The mean of at least 5 consecutive blood pressure readings from each pig was used from a 
given session for statistical analyses.  Finally, blood gases were measured in venous blood 
collected from the jugular vein into blood gas syringes ((Radiometer PICO 50; Radiometer; 
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Copenhagen, Denmark). Oxygenated hemoglobin (oxyHb), carboxy-hemoglobin (CO-Hb), 
methemoglobin (MetHb) and total hemoglobin (TotalHb) levels were measured using a 
Rapidlab 865 blood gas analyzer (Bayer Diagnostics, East Walpole, MA, USA). Ultrasound, 
blood pressure and blood gas measurements were taken at baseline (i.e. Day 0 or prior to 
starting the exposures), day 1, day 7, and day 14, of the experiment.   
 
5.2.4.Plasma nitrate/nitrite, cotinine, nitrotyrosine, C-reactive protein (CRP), and 
ethoxyresorufin-o-deethylase (EROD) activity 
Blood samples were collected from all pigs at baseline and on the last day of experiments 
into EDTA or serum vacutainers for plasma and serum, respectively, and stored on ice until 
spun at 4000xg for 10 minutes. Plasma and serum were aliquoted, then stored at -80C until 
used in assays. Plasma nitrate/nitrite (NOx) levels were assessed using a commercially 
available enzyme-based kit (NO Quantitation Kit, Active Motif North America, Carlsbad, 
USA). Plasma cotinine (Bio-Quant, Inc, San Diego, USA), plasma nitrotyrosine (Cell 
Sciences, Canton, USA) and serum CRP (CRP; Geneway Biotech, CA, USA) levels were 
measured using commercially available enzyme-linked immunosorbent assays. Liver and 
lung homogenates were used to produce microsomes from all pigs and were then analyzed 
for CYP1A1 using EROD activity, as previously described (Weber et al., 2002).  
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5.2.5.Bronchoalveolar lavage (BAL) fluid differential, total cell count and leukocyte 
elastase activity  
At the end of each experiment pigs were euthanized by an intravenous injection with 
pentobarbital sodium (Euthanol; 100 mg/kg). Bronchoalveolar lavage  was performed by 
infusing 40 ml of normal saline into the isolated trachea and lungs, with 20 ml of the lavage 
fluid retrieved in this process. First a hemocytometer was used to determine the total white 
blood cell count, then a cytospin preparation stained with Wright’s solution was used to 
determine the differential cell counts in each BAL sample. Bronchoalveolar lavage  fluid 
leukocyte elastase activity was measured using a synthetic substrate i.e. N-succinyl-(ala)3-p-
nitroanilide (Sigma-Aldrich, ON, Canada) as previously described (Castillo et al., 1979). The 
activity of the enzyme was measured in units in which one unit of leukocyte elastase released 
one nanomole of p-nitrophenol per sec from BOC-L-alanine p-nitrophenyl ester at pH 6.5 at 
37 °C. 
 
5.2.6.Histological and morphometric analysis 
Following euthanasia, tissues from the heart, lung, liver as well as aorta, coronary and 
brachial arteries were collected and placed in 10% formalin. Tissues were paraffin-
embedded, serial 5 μm sections cut, stained with hematoxylin and eosin (H& E), and 
mounted with Micromount (Surgipath, AB, Canada).  All tissues were evaluated for 
histopathological changes by a veterinary pathologist. For each artery, morphometric digital 
analyses were performed on 3 images captured from 3 different sections. Histological 
micrographs were taken using an Olympus BX41 microscope, attached to an Olympus DP71 
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digital camera, and captured using DP controller software (Olympus Canada Inc., Markham, 
Canada).  Image Pro Plus7 was used to trace and measure the internal perimeter and wall 
thickness (WT) of each of the 3 images, and averages were then determined. From each 
perimeter the luminal diameter (LD) was calculated using the formula: diameter = P/ , and 
the ratio of LD to WT (LD/WT) was also determined. 
5.2.7.Statistical analysis 
Statistical analysis was performed using GraphPad Prism 5.03 (GraphPad Software, San 
Diego, CA, USA) or Systat 11 (Chicago, IL, USA). In order to correct for individual 
variation in baseline measurements that occurred among pigs, all subsequent measurements 
were normalized by dividing by their corresponding baseline values from the same pig. 
Differences among groups were analyzed by three-way analysis of variance (ANOVA) with 
ETS, RES and time as factors followed by modified Bonferroni posteriori tests. Terminal end 
points were analyzed by a two- way ANOVA with RES and ETS as factors. A p-value < 0.05 
was considered significant. All data were expressed as mean ± standard error of the mean 
(SEM).   
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5.3. Results 
5.3.1.Exposure conditions, flow mediated dilation (FMD), echocardiography, blood 
pressure, and blood gases evaluation 
Chamber conditions during ETS and sham exposures are summarized in Table 5.1. In 
general, the levels of CO and total particulates were higher during ETS exposures than 
control exposures. Chamber O2 levels decreased after ETS exposure compared to sham 
exposure, but remained 21%. In contrast, CO2 levels remained below the detection limit 
(<0.5%) during both exposures. Serum cotinine levels after 4-weeks exposure were 
significantly higher in ETS-exposed and ETS+RES-treated group compared to corresponding 
sham-exposed pigs (Table 5.1).  
In order to assess the effects of ETS and RES on cardiovascular function in vivo, 
ultrasound and blood pressure assessments were performed weekly in pigs. A significant 
decrease in FMD was noted over time and FMD was further decreased by 7 days of ETS 
treatment, but with a significant interaction between the two variables (Figure 5.1). 
Resveratrol treatment alone or with ETS exposure had no effect on FMD. More importantly, 
FMD remained impaired in pigs receiving RES + ETS treatment compared to ETS treatment 
alone. Left ventricular end-diastolic volume (EDV), end-systolic volume (ESV) and ejection 
fraction (EF) increased significantly in a time-dependent manner as the pigs continued to 
grow (Table 5.2). ETS exposure showed no significant effect on EDV, ESV or EF, even after 
14 days of treatment (Table 5.2). In contrast, ETS exposed pigs receiving RES treatment 
showed a significant increase in EF compared to ETS pigs (Figures 5.2 & 5.3). Additionally,  
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Table 5.1: Chamber conditions during environmental tobacco smoke (ETS) or sham 
exposures. Plasma cotinine concentrations in pigs from ETS and sham groups without and 
with resveratrol treatment (-RES and +RES, respectively; n=4/group) after 14 days of 
exposure. Temperature and carbon monoxide (CO) were continuously monitored for 1 hr 
during ETS or sham exposure, and were expressed as a mean of 3 readings taken every 20 
minutes.  Particulates were sampled continuously during 1 hr sham or ETS exposure and are 
expressed as total particulate matter/hr.  A total of 11-12 cigarettes were burned during the 
daily ETS exposure or air pumped through unlit cigarettes for sham exposures. Data are 
expressed as mean ± standard error. *p<0.05 compared to sham in unpaired t-test with 
Welch’s correction. #p<0.05 compared to corresponding sham group in modified Bonferroni 
test after two-way analysis of variance (ANOVA) with ETS and RES as factors.   
 
 Sham         ETS 
Temperature  24ºC       23ºC 
CO (mean) 0       136 ppm 
Particulates 
O2 
CO2 
30 μg/m3 
24% 
<0.5% 
      110 μg/m3 
      21%          
       <0.5% 
Cotinine    -RES 
(ng/mL) 
3.76  0.36        31.27  4.87* 
                 +RES 4.21  0.24         35.4   4.13* 
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Figure 5.1 Time-course of changes in flow mediated dilation after daily 1-hr sham or 
environmental tobacco smoke (ETS) exposure, either with or without oral resveratrol (RES; 
5mg/kg) treatment for 14 days. Data for each animal (n=4 per group) are expressed as a 
percent of the baseline (or pre-exposure) response in the same individual. Data were analyzed 
by three-way analysis of variance (ANOVA) with ETS, RES and time as factors, and 
expressed as mean  standard errors of the means (SEM). *p<0.05 in modified Bonferroni 
posteriori test after three-way ANOVA. A significant interaction was found between ETS 
and time (p<0.001). No other interactions were found. 
 
 
Baseline 1 7 14
0
50
100
150
Sham
RES
ETS
ETS + RES
*
*
*
*
ETS p<0.001
RES p=0.788
Time p<0.001
 
Time (days)
F
lo
w
 m
e
d
ia
te
d
 d
il
a
ti
o
n
%
 84 
  
 
Figure 5.2 Time-course of changes in left ventricular ejection fraction (EF) after daily 1-hr 
sham or environmental tobacco smoke (ETS) exposure, either with or without oral 
resveratrol (RES; 5mg/kg) treatment for 14 days. Data for each animal (n=4 per group) are 
expressed as a percent of the baseline (or pre-exposure) response in the same individual. Data 
were analyzed by three way analysis of variance (ANOVA) with ETS, RES and time as 
factors, and expressed as means  standard errors of the means (SEM). *p<0.05 in modified 
Bonferroni posteriori test after three-way ANOVA. No significant interactions among 
ANOVA factors were found. 
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Figure 5.3  Time-course of changes in left ventricular end diastolic volume after daily 1-hr 
sham or environmental tobacco smoke (ETS) exposure, either with or without oral 
resveratrol (RES; 5mg/kg) treatment for 14 days. Data for each animal (n=4 per group) are 
expressed as a percent of the baseline (or pre-exposure) response in the same individual. Data 
were analyzed by three way analysis of variance (ANOVA) with ETS, RES and time as 
factors, and expressed as means  standard errors of the means (SEM). *p<0.05 for time 
factor in modified Bonferroni posteriori test after three-way ANOVA. No significant 
interactions among ANOVA factors were found. 
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RES treatment resulted in a significant overall increase in EDV but had no effect on ESV 
(Table 5.2).   
Heart and body weight were determined at the termination of the experiment. No 
significant difference was found in heart weight, body weight or heart/body weight ratio 
between all groups (Table 5.3). Blood pressure (systolic, diastolic, mean and pulse pressures) 
was not significantly altered over time or any treatment type (Table 5.4). In contrast, ETS 
exposure and RES treatment both caused a significant overall decrease in MetHb (Figure 
5.4). However, neither ETS nor RES had any effect on OxyHb, CO-Hb or TotalHb (Table 
5.5)  
5.3.2.Plasma nitrate/nitrite, nitrotyrosine, C-reactive protein (CRP), and 
ethoxyresorufin-o-deethylase (EROD) activity 
Overall, serum nitrate/nitrite levels (an indicator of NO production) were highly variable 
and no significant changes were observed over time or as a result of any treatment (Table 
5.6). In contrast, ETS exposure caused a significant increase in serum nitrotyrosine levels (an 
indicator of NO inactivation by superoxide free radical via peroxynitrite formation) 
compared to sham exposure (Figure 5.5). On the other hand, RES treatment alone or with 
ETS exposure had no effect on nitrotyrosine levels compared to the corresponding group 
without RES treatment (Figure 5.5). Similarly ETS exposure resulted in a significant increase 
in serum CRP levels compared to sham exposure, both in the presence and absence of RES 
treatment (Figure 5.6). Resveratrol treatment alone had no effect on CRP levels (Figure 5.6).  
A significant increase in lung, but not liver EROD activity was found after ETS exposure 
compared to sham exposure  
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Table 5.2: Absolute values obtained for left ventricular end diastolic volume (EDV), end 
systolic volume (ESV), and ejection fraction (EF) determined over time after daily 1-hr sham 
or environmental tobacco smoke (ETS) exposure, either with or without oral resveratrol 
(RES; 5mg/kg) treatment for 14 days (n=4 pigs/group). Data are expressed as mean  
standard error of the mean. Absolute values are shown for qualitative evaluation only since 
statistical analyses were performed on data normalized to pre-exposure values and results 
with significant changes are shown in corresponding figures.    
 
 Treatment Baseline Day 1 Day 7 Day 14 
 
ESV (ml) 
Sham 
RES 
ETS 
RES+ETS 
3.4±0.3 
3.8±0.4 
3.5±0.2 
3.8±0.4 
3.3±0.3 
4.5±0.7 
4.5±0.3 
3.4±0.3 
4.7±0.6 
4.4±0.5 
5.1±0.3 
5.2±0.7 
5.6±0.6 
5.2±0.7 
5.8±0.5 
5.3±0.9 
 
EDV (ml) 
Sham 
RES 
ETS 
RES+ETS 
7.5±0.3 
7.3±0.4 
7.4±0.5 
7.2±0.5 
8.1±0.7 
9.5±0.3 
8.5±0.3 
8.9±0.2 
10.5±0.4 
11.3±0.5 
10.6±0.8 
12.3±1.2 
15.5±0.8 
13.6±0.6 
13.1±0.5 
15.9±1.6 
 
EF (%) 
Sham 
RES 
ETS 
RES+ETS 
54±4 
49±4 
52±3 
47±5 
59±1 
54±6 
47±2 
61±3 
55±6 
61±5 
60±4 
58±4 
54±2 
62±5 
56±3 
67±3 
 
 
 88 
  
Table 5.3: Heart weight, body weight and heart / body weight ratio after daily 1-hr sham or 
environmental tobacco smoke (ETS) exposure, either with or without oral resveratrol (RES; 
5mg/kg) treatment for 14 days (n=4 pigs/group). Data are expressed as mean  standard error 
of the mean. No significant differences were detected using a two way analysis of variance 
with ETS and RES as factors. 
 
 Heart weight (Kg) Body weight (Kg) Heart / Body weight (%) 
Sham 
RES 
ETS 
RES+ETS  
0.163  0.013  
0.178  0.004  
0.162  0.015  
0.177  0.003  
18.19  1.37 
20.94  2.08 
20.38  3.06 
20.39  1.42 
0.89  0.03  
0.87  0.07 
0.83  0.09 
0.88  0.04  
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Table 5.4: Absolute values for systolic, diastolic, mean arterial and pulse pressure (mmHg) 
over time after daily 1-hr sham or environmental tobacco smoke (ETS) exposure, either with 
or without oral resveratrol (RES; 5mg/kg) treatment for 14 days (n=4 pigs/group). Data are 
expressed as mean  standard error of the mean. Absolute values are shown for qualitative 
evaluation only since statistical analyses were all performed on data normalized to pre-
exposure values and results with significant changes are shown in corresponding figures.  
` Treatment Baseline Day 1 Day 7 Day 14 
Systolic 
pressure 
(mm Hg) 
 
Sham 
RES 
ETS 
RES+ETS 
120±9 
135±10 
123±11 
121±11 
110±14 
126±5 
127±11 
140±14 
133±7 
129±6 
118±21 
127±14 
137±8 
127±14 
126±12 
139±10 
Diastolic 
pressure 
(mm Hg) 
 
Sham 
RES 
ETS 
RES+ETS 
59±8 
60±1 
56±3 
61±5 
52±3 
63±2 
60±5 
58±7 
56±3 
55±3 
57±4 
52±4 
55±3 
56±3 
54±4 
57±4 
Mean 
arterial 
pressure 
(mm Hg) 
Sham 
RES 
ETS 
RES+ETS 
81±8 
87±3 
79±5 
82±6 
72±6 
86±3 
83±7 
86±9 
83±3 
81±3 
79±10 
79±6 
83±4 
81±7 
79±6 
86±6 
Pulse 
pressure 
(mm Hg) 
Sham 
RES 
ETS 
RES+ETS 
61±7 
75±11 
67±10 
60±9 
58±12 
63±3 
68±7 
83±10 
77±8 
74±6 
61±18 
75±11 
82±5 
71±11 
72±10 
82±7 
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Figure 5.4: Time course of changes in methemoglobin (MetHb) levels after daily 1-hr sham 
or environmental tobacco smoke (ETS) exposure, either with or without oral resveratrol 
(RES; 5mg/kg) treatment for 14 days. Data for each animal (n=4 per group) are expressed as 
a percent of the baseline (or pre-exposure) response in the same individual. Data were 
analyzed by three way analysis of variance (ANOVA) with ETS, RES and time as factors, 
and expressed as means  standard errors of the means (SEM). *p<0.05 by Bonferroni 
posteriori test after three-way ANOVA. No interactions were found.
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Table 5.5: Time course of change in venous blood oxyhemoglobin (OxyHb) carboxy-hemoglobin 
(CO-Hb), methemoglobin (MetHb) and total hemoglobin (TotalHb) after daily 1-hr sham or 
environmental tobacco smoke (ETS) exposure, either with or without oral resveratrol (RES; 5mg/kg) 
treatment for 14 days (n=4 pigs/group). Data are expressed as mean  standard error of the mean. 
Absolute values are shown for qualitative evaluation only since statistical analyses were performed on 
data normalized to pre-exposure values and results with significant changes are shown in the 
corresponding figures. 
 Treatment Baseline Day 1 Day 7 Day 14 
 
OxyHb 
(%) 
 
Sham 
RES 
ETS 
RES+ETS 
88±7 
72±11 
86±5 
86±8 
72±8 
73±7 
76±6 
67±5 
64±5 
74±5 
69±8 
73±2 
75±6 
73±7 
76±10 
74±8 
 
CO-Hb 
(%) 
 
Sham 
RES 
ETS 
RES+ETS 
0.13±0.03 
0. 10±0.00 
0.10±0.00 
0.08±0.03 
0.08±0.05 
0.10±0.00 
0.08±0.03 
0.13±0.03 
0.08±0.03 
0. 10±0.00 
0.13±0.08 
0.13±0.03 
0.05±0.03 
0.09±0.04 
0.05±0.03 
0.08±0.03 
 
MetHb 
(%) 
 
Sham 
RES 
ETS 
RES+ETS 
1.85±0.01 
2.30±0.24 
2.18±0.18 
2.45±0.41 
2.35±0.29 
2.68±0.17 
2.65±0.65 
2.13±0.42 
2.63±0.16 
2.85±0.10 
3.30±0.45 
2.13±0.17 
2.60±0.21 
2.42±0.27 
2.53±0.31 
2.28±0.19 
 
TotalHb 
(%) 
Sham 
RES 
ETS 
RES+ETS 
102±9 
105±4 
106±2 
102±9 
100±11 
96±3 
100±7 
98±3 
92±8 
99±7 
100±4 
104±4 
102±5 
96±8 
103±10 
114±5 
 92 
  
Table 5.6: Time course of change in total plasma nitrate/nitrite level after daily 1-hr sham or 
environmental tobacco smoke (ETS) exposure, either with or without oral resveratrol (RES; 
5mg/kg) treatment for 14 days (n=4 pigs/group). Data are expressed as mean  standard error 
of the mean. Absolute values are shown for qualitative evaluation only since statistical 
analyses were performed on data normalized to pre-exposure values. No statistically 
significant differences were detected using three-way analysis of variance (ETS, RES and 
time as factors). 
 
 Total nitrate/nitrite (µM) 
 Sham RES ETS RES+ETS 
Baseline 
Day 1 
Day 14 
5.12  1.78 
2.42  1.02 
5.20  1.46 
6.37  1.68 
4.10  0.50 
1.73  0.57 
5.73  1.60 
5.13  1.62 
1.77  0.55 
8.87  1.79 
5.78  1.66 
3.39  0.86 
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Figure 5.5: Serum nitrotyrosine levels after 14 days of daily 1-hr sham or environmental 
tobacco smoke (ETS) exposure, either with or without oral resveratrol (RES; 5mg/kg) 
treatment (n=4 pigs/group). Data are expressed as mean  standard error of the mean. 
*p<0.05 in modified Bonferroni posteriori test after two-way analysis of variance (ETS and 
RES as factors).  
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Figure 5.6: Serum C-reactive protein (CRP) levels after 14 days of daily 1-hr sham or 
environmental tobacco smoke (ETS) exposure, either with or without oral resveratrol 
(RES; 5mg/kg) treatment (n=4 pigs/group). Data are expressed as mean  standard error 
of the mean. 
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(Figure 5.7). Resveratrol treatment alone had no effect on either lung or liver EROD activity 
and also had no effect on ETS-mediated increases in lung EROD activity (Figure 5.7). 
 
5.3.3.Bronchoalveolar lavage (BAL) fluid total white blood cell count, BAL 
differential cell count, BAL leukocyte elastase activity and tissue histology   
The total WBC count in BAL fluid was significantly increased after 14-days of daily ETS 
exposure (Figure 5.8), but not after sham exposure. Resveratrol treatment alone or in 
combination with ETS had no effect on BAL total WBC count (Figure 5.8). Macrophages 
were the only inflammatory cell type found within BAL fluid from all treatments. A 
qualitative evaluation of histological lung sections also showed an increase in intra-alveolar 
macrophages in ETS-exposed pigs compared to sham-exposed pigs, both in the presence and 
absence of RES, with no histological evidence of emphysema (i.e. no enlarged air sacs; 
Figure 5.9). A small, but significant increase in BAL fluid leukocyte elastase activity was 
found after ETS exposure in the overall two-way ANOVA analysis (Figure 5.10). However 
no significant differences in BAL fluid leukocyte elastase activity were found in subsequent 
pair-wise posteriori comparisons (Figure 5.10). No histopathological lesions were detected in 
any other tissue that was evaluated; liver, heart or arteries (Figure 5.11). Finally, there were 
no significant differences in arterial wall thickness or arterial diameter (evaluated as luminal 
diameter, wall thickness or a ratio of the two) in aorta, brachial artery or coronary artery 
among all treatment groups (Table 5.7). 
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Figure 5.7: Ethoxyresorufin-o-deethylase (EROD) activity in lung (A) and liver (B) 
microsomes prepared from pigs after 14 days of daily 1-hr sham or environmental tobacco 
smoke (ETS) exposure, either with or without oral resveratrol (RES; 5mg/kg) treatment (n=4 
pigs/group). Data are expressed as mean  standard error of the mean. *p<0.05 in modified 
Bonferroni posteriori test after two-way analysis of variance.  
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Figure 5.8: Total white blood cell count in bronchoalveolar lavage (BAL) fluid collected 
from pigs after 14 days of daily 1-hr sham or environmental tobacco smoke (ETS) exposure, 
either with or without oral resveratrol (RES; 5mg/kg) treatment (n=4 pigs/group). Data are 
expressed as mean  standard error of the mean. *p<0.05 in modified Bonferroni posteriori 
test after two-way analysis of variance.  
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Figure 5.9: Representative hematoxylin-eosin-stained lung sections from pigs after 14 days of daily 1-hr sham or environmental 
tobacco smoke (ETS) exposure, either with or without oral resveratrol (RES; 5mg/kg) treatment. Lungs from ETS-exposed pigs, 
both with and without RES treatment, showed increased alveolar macrophages (indicated with arrows). Bar on micrographs 
indicates 50 m. 
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Figure 5.10: Leukocyte elastase concentration in bronchoalveolar lavage (BAL) fluid 
collected from pigs after 14 days of daily 1-hr sham or environmental tobacco smoke (ETS) 
exposure, either with or without oral resveratrol (RES; 5mg/kg) treatment (n=4 pigs/group). 
Data are expressed as mean  standard error of the mean. *p<0.05 in modified Bonferroni 
posteriori test   after two-way analysis of variance. U = one unit of leukocyte elastase 
releases one nanomole of p-nitrophenol per sec from BOC-L-alanine p-nitrophenyl ester at 
pH 6.5 at 37 °C. 
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Figure 5.11. Representative hematoxylin-eosin-stained sections of liver (A,B,C,D), heart with accompanying coronary artery 
(E,F,G,H) and brachial artery (I,J,K,L) collected from pigs after 14 days of daily 1-hr sham or environmental tobacco smoke 
(ETS) exposure, either with or without oral resveratrol (RES; 5mg/kg) treatment. No histopathological lesions were observed in 
any of these organs in any treatment group. Bar on micrographs indicates 1.0 mm. 
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Table 5.7: Wall thickness and diameter of arteries after 14 days of daily 1-hr sham or environmental tobacco smoke (ETS) 
exposure, either with or without oral resveratrol (RES; 5mg/kg) treatment (n=4 pigs/group). Luminal diameter (LD), wall 
thickness (WT) and luminal diameter/wall thickness (LD/WT) of aorta, brachial and coronary arteries were determined by digital 
morphometric analyses of hematoxylin/eosin-stained sections. Data are expressed as mean  standard error of the mean. No 
statistically significant differences were detected using separate two-way analyses of variances with ETS and RES as factors. 
 
                   Coronary artery Brachial artery Aorta 
 LD WT LD/WT LD WT LD/WT LD WT LD/WT 
Sham 
RES 
ETS 
RES+ETS 
1.270.04 
1.220.03 
1.240.04 
1.230.03 
0.180.01 
0.180.01 
0.190.01 
0.180.01 
7.30.4 
6.60.4 
6.70.2 
6.90.6 
2.190.10 
2.240.20 
2.230.05 
2.180.08 
0.350.01 
0.330.01 
0.360.01 
0.330.02 
6.40.3 
6.80.3 
6.20.3 
6.70.5 
4.730.24 
4.710.27 
4.860.23 
4.470.32 
0.800.05 
0.810.06 
0.770.07 
0.830.05 
5.90.4 
5.90.7 
6.40.8 
5.40.3 
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5.4. Discussion 
The most important finding of this study is that, similar to a previous study from this 
laboratory, exposure to daily 1-hr ETS impaired vascular endothelial function as early as 7 
days, with further impairment by 14 days. However, RES failed to reverse the ETS-mediated 
FMD impairment. Additionally, ETS exposure resulted in systemic inflammation, increased 
oxidative stress and increased biological inactivation of NO, all of which can cause 
endothelial dysfunction. Within the lung, ETS exposure resulted in lung inflammation, 
increased lung EROD activity, increased total WBC count (macrophages) in BAL fluid and 
increased BAL leukocyte elastase activity without histological evidence of emphysema. 
Finally, co-treatment with RES and ETS improved cardiac function (increased left 
ventricular EDV and EF) compared to ETS alone, which suggests that RES improves venous 
return. However, RES treatment failed to mitigate other ETS-mediated effects including 
systemic inflammation, oxidative stress or any effects on the lung.  Taken together, these 
results suggest that systemic and pulmonary inflammatory responses are important links to 
endothelial dysfunction, and that the favorable cardiovascular effects of RES may be related 
to its effect on cardiac function only.  
RES is a natural substance extracted from the skin and seeds of red grapes. Some studies 
have claimed it has anti-atherogenic and cardiovascular protective properties (Csiszar et al., 
2008). Although RES has high bioavailability after oral administration, it is rapidly 
metabolized by the liver and only trace amounts of unchanged RES are available (Walle et 
al., 2004). Therefore, an oral dose that was in the high end of that previously shown to be 
non-toxic in chronic rat feedings (Rocha et al., 2009) and to have beneficial effects on FMD 
in obese, pre-hypertensive humans (Wong et al.) was used to maximize the chance of 
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observing RES effects. However, in the current study, RES did not improve ETS-mediated 
decreases in FMD or reverse the ETS-induced increase in serum nitrotyrosine and CRP. This 
in contrast with in vitro findings that RES has antioxidant (Kawada et al., 1998) and anti-
inflammatory (Donnelly et al., 2004) effects. However, others have also reported that RES is 
pro-oxidant (Ahmad et al., 2003), promotes atherosclerosis (Wilson et al., 1996) and does 
not reach the lung after oral administration (Berge et al., 2004). Furthermore, RES failed to 
exert a beneficial cardiovascular effect in rats fed a normal-fat diet, while exerting a 
protective effect when the rats were fed high-fat chow (Wang et al., 2005). Taken together, 
these results suggest RES may exert a protective effect in obesity and hyperlipidemia, but not 
after ETS exposure. Since obesity, high fat diets and ETS exposure have all been shown to 
increase oxidative stress, the failure of RES to mitigate ETS-mediated FMD effects suggests 
that RES is not providing cardiovascular protection solely via antioxidant mechanisms.  
Similar to what was found in human beings (Peluffo et al., 2009b), the exposure of pigs 
to ETS resulted in impairment of FMD. Several studies have reported that brachial artery 
FMD is completely NO dependent in humans (Green, 2005). Serum nitrate/nitrite levels have 
been used as surrogate marker for eNOS activity and NO production. It has been shown that 
cigarette smoke decreases eNOS activity in a dose-dependent manner in human beings 
(Zhang et al., 2006). Moreover, free radicals within cigarette smoke react with NO to 
produce peroxynitrite, thereby decreasing NO bioavailability (Zhang et al., 2006). In support 
of this, the current study found elevated serum nitrotyrosine (a by-product of peroxynitrite) 
levels without a change in total NO production after ETS exposure, suggesting that decreased 
NO bioavailability may be related to the impairment of FMD after ETS exposure in pigs.  
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Endothelial dysfunction may have a negative impact on cardiac function. By causing 
arterial stiffness, this leads to increased peripheral resistance, increased afterload and 
hypertension. However, no change in blood pressure was observed in the current study, 
disagreeing with known acute cardiostimulatory effects known for nicotine. Although 
nicotine is the constituent that is responsible for cigarette smoke addiction, it does not 
explain the chronic effects of cigarette smoke or ETS exposure (Rahman and Laher, 2007). 
Even in the absence of blood pressure changes, an increase in vascular tone and 
hemodynamic overload may still cause myocardial systolic dysfunction because the heart has 
to work harder to eject blood against the increased afterload (Borlaug et al., 2009). 
Furthermore, a prolonged increase in afterload causes left ventricular hypertrophy and 
alteration in left ventricular extracellular matrix (Verma and Solomon, 2009) which would 
then contribute to diastolic dysfunction. Although several studies have provided supportive 
evidence that acute and chronic exposure to cigarette smoke impairs left ventricular diastolic 
function (Alam et al., 2002; Gulel et al., 2007) and enhances the progression of 
hypertension-induced myocardial hypertrophy in spontaneously hypertensive rats (Meurrens 
et al., 2007), the current study failed to detect a significant ETS-mediated effect on left 
ventricular function. In the current study, the observed increase in EDV and ESV over time 
regardless of treatment, in the absence of structural or pathological changes, is clearly related 
to growth of the pigs. Furthermore, the echocardiographic technique used in the current study 
appears sufficiently sensitive since RES was found to significantly improve left ventricular 
function when co-administered with ETS exposure. Since RES failed to reverse ETS-
mediated impairments in FMD, it is unlikely that the effect on ventricular function (improved 
EF and EDV) is secondary to improvements in endothelial function. Instead, RES may be 
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exerting a direct cardio-protective effect similar to that previously reported in humans 
(Penumathsa et al., 2008).  
Tobacco smoke contains carbon monoxide and many unstable, reactive molecules that 
would increase the levels of CO-Hb and MetHb, respectively,  (Borland et al., 1985). 
Possibly due to effects of elevated CO-Hb and chronic hypoxia, hemoglobin levels are 
reported to be 0.3-4% higher in smokers compared to nonsmokers (Andrews and Tingen, 
2006). In this study, no significant differences in TotalHb, OxyHb or CO-Hb levels were 
found after ETS exposure despite slightly lower levels of O2 and higher levels of CO in the 
exposure chamber. In addition to known vasodilatory effects of CO (Achouh et al., 2008), it 
has been shown that endothelial cells produce peroxynitrite after CO exposure (Thom et al., 
1997), suggesting that CO by itself can also stimulate oxidative stress. Thus, CO does not 
appear to be responsible for the observed ETS-mediated FMD impairment in the current 
study. By definition, MetHb is the oxidized form of hemoglobin and levels have been 
reported to increase in the presence of the oxidative stress caused by smoke exposure (Wright 
et al., 1999). In contrast, the results of the current experiment with ETS and RES co-
exposure are consistent with another previous study that reported decreased MetHb after ETS 
(Borland et al., 1985). The decreased MetHb result suggests lower oxidative stress, but this is 
inconsistent with the increased plasma nitrotyrosine observed after ETS exposure.  
Polycyclic aromatic hydrocarbons are lipophilic compounds which result from the 
combustion of organic material (Tithof et al., 2002). Many of the actions of PAHs are 
mediated by a ligand activated transcription factor known as the Ahr (Korashy and El-Kadi, 
2006). By binding to the xenobiotic response element on DNA, this transcription factor 
causes transcriptional induction of dioxin-responsive genes such as the detoxification 
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enzyme, CYP1A1 (Korashy and El-Kadi, 2006). In vitro experiments have shown that RES 
can antagonize Ahr (Casper et al., 1999), but the failure of RES to diminish ETS-mediated 
increases in lung CYP1A1 in the current study supports recent studies showing a lack of in 
vivo antagonistic effect (Bugiak and Weber, 2009; Canistro et al., 2009). The metabolism of 
PAHs by CYP1A1 may be mechanistically important since it results in the formation of 
highly reactive metabolites which, in turn, can form adducts with DNA and protein (Korashy 
and El-Kadi, 2006; Moorthy et al., 2003). Additionally, PAH metabolites can be metabolized 
to quinone structures which can undergo redox cycling to produce ROS (Korashy and El-
Kadi, 2006; Moorthy et al., 2003). Similar to previous reports in humans (Anttila et al., 
2001), the inhalation exposure of pigs to ETS resulted in CYP1A1 induction within the lung. 
Since the lungs are the point of entry for these ETS exposures, it seems logical that all Ahr 
agonists within ETS were metabolized within the lungs without escaping into the systemic 
circulation since liver CYP1A1 activity was unchanged. However, the possibility that 
reactive metabolites escaped the lung and entered the systemic circulation to increase 
oxidative stress requires clarification with further experiments.  
Alternatively,  increased systemic oxidative stress could be caused by systemic 
inflammation (Taddei et al., 2006). C-reactive protein is a marker for systemic inflammation 
produced by the liver and is elevated in human smokers (Antoniades et al., 2004; May and 
Wang, 2007), after ETS exposure in humans (Gan et al., 2005), as well as in the current 
study after ETS exposure in pigs. Small increases in serum CRP are also used as a predictor 
for CVD such as coronary heart disease (Antoniades et al., 2004; May and Wang, 2007). The 
observation that active cigarette smoking causes lung inflammation has been reported based 
on the presence of neutrophils and macrophages within alveoli (van der Vaart et al., 2004), 
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and was consistent with the increased total WBC count within the BAL fluid after ETS 
exposure in current study. In contrast, macrophages, not neutrophils, were the only cell type 
observed in the BAL fluid after ETS exposure in the current experiment. Also, it is important 
to note that RES did not show any ability to reverse ETS-mediated lung inflammation in the 
current study, suggesting that RES does not exert any anti-inflammatory action in this pig 
ETS model.  Inflammation within the airways is known to promote decreased lung function, 
asthma and respiratory irritation in children and adults passively exposed to ETS (Chan-
Yeung and Dimich-Ward, 2003; Salvi and Barnes, 2009). Pulmonary neutrophils and 
macrophages not only generate ROS and inflammatory cytokines that can impair endothelial 
function (Fujii et al., 2002), but also release extracellular matrix degrading enzymes i.e. 
elastases which contribute to lung emphysema (Sharafkhaneh et al., 2008). Consistent with 
other studies (Lucattelli et al., 2005; Maeno et al., 2007) the BAL fluid leukocyte elastase 
activity was increased after ETS exposure in the current experiment. This suggests that ETS-
mediated inflammation was sufficient to have started emphysema pathogenesis by 14 days of 
exposure in pigs.  However, the absence of histological evidence of lung emphysema in this 
study also indicates that the relatively short duration (14 days) of ETS exposure had 
produced only non-structural and more likely reversible changes in the lung.  
In conclusion, the critical observations of the current study were that ETS exposure 
caused impaired endothelial function with evidence of systemic and lung inflammation, 
increased lung CYP1A1 activity and oxidative stress. In contrast, RES failed to reverse any 
ETS-induced effects, but did appear to exert a direct effect on the heart that led to improved 
left ventricular function. Considering the high dose level of RES used in the current study, 
the failure of RES is unlikely to be due to insufficient levels, but rather may be due to a lack 
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of efficacy in pigs or in ETS-induced lung inflammation. Future experiments are needed to 
confirm whether this is pig-specific difference in efficacy or a more generalized 
ineffectiveness of RES to ameliorate ETS-mediated cardiovascular effects.  
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6. Discussion & Conclusion 
6.1. Similarities and differences in findings between studies in this thesis 
Environmental tobacco smoke exposure resulted in similar changes to the end points 
measured after 2 or 4 week exposure to ETS. Similar changes were noted for FMD, CRP, 
nitrotyrosine, liver and lung EROD, and BAL fluid total WBC counts, which indicates that 
ETS can have negative health effects after as little as 14 days of exposure. The 
reproducibility of results between the two studies also strengthens our conclusions. 
Differences between the two ETS exposure experiments were noted in cardiac assessment 
and also in BAL fluid leukocyte elastase activity. This could be due to differences in length 
of exposure between the two experiments. The variability could also be related to small 
sample sizes and technical errors during assessment. The choice of sample size was based on 
power analysis aimed at detecting differences in FMD. However, our ability to consistently 
detect changes in cardiac size with growth further emphasizes the reliability of our 
echocardiography assessment. Surprisingly, the BAL fluid leukocyte elastase activity was 
significantly elevated in the second ETS exposure experiment despite its shorter duration. It 
should be noted, however, that a similar trend for change was noted in first ETS exposure 
experiment. Thus, the differences here may related to individual variability and could thus be 
related to low sample numbers.  
In the first experiment the differences between the length of BAP and ETS exposure may 
explain the absence of change in FMD after BAP exposure. However, changes in FMD were 
noted as early as 7 days after ETS exposure and the dose at which BAP was administered is 
many orders of magnitude higher than what is found in cigarette smoke. Instead, the 
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difference in route of exposure (inhalation versus intravenous injection) seems to indicate 
that lung inflammation is a key element in FMD impairment. A possible mechanism by 
which endothelial function is impaired preferentially by lung inflammation is discussed 
further in a following section. 
 
6.2. Resveratrol’s effects 
Oral resveratrol administration did not reverse any of the negative effects of ETS, which 
indicates that RES may not possess the claimed desirable cardiovascular effects which were 
largely based on results from in vitro testing. This failure of RES may not have been due to a 
low dosage of RES since the dose used was at least 3-4 times higher than what is 
recommended by the manufacturer (100mg/day for adults). Moreover, the dose chosen for 
this thesis falls within the range of commonly used doses, including several studies reporting 
beneficial effects with similar or lower doses in rats and mice (Jin et al., 2010; Lekli et al., 
2008; Palsamy et al.; Silvia et al., 2007). 
The effects of RES versus BAP were predicted to be opposite if both work via interaction 
with Ahr (antagonist and agonist, respectively). The results of this thesis do not support this 
hypothesis because Ahr-related changes were seen only after BAP exposure. The increase in 
liver EROD activity after BAP exposure indicates that its effects are mediated at least in part 
through activation of Ahr. The failure of RES to reverse the Ahr-mediated effects of BAP 
within cigarette smoke does not support the claim that RES is an Ahr antagonist. In fact, it 
has been shown recently that RES may actually be a partial agonist of Ahr (Bachleda et al., 
2010).  More importantly, RES has more recently been shown to exert effects through SIRT-
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1 which may be a more important mechanism of action for beneficial health effects than AhR 
interaction (Borra et al., 2005) . 
 
6.3.  Synthesis of tobacco smoke effects on the lung and proposed mechanism of action 
It is estimated that cigarette smoke contain 5 x 10
14
 free radicals / puff, and cigarette 
smoke exposure results in an inflammatory response within the lung characterized by the 
presence of neutrophils and/or macrophages within alveolar spaces. Lung components 
including epithelial cells, fibroblasts and resident pulmonary macrophages respond to the 
smoke particulate exposure by releasing a number of chemotactic factors such as IL-8, LTB-
4, MIP-1 and MCP-1 which attract neutrophils and monocytes into the lung (van der Vaart et 
al., 2004; Wright et al., 2002). Experimentally, increased or unchanged numbers of 
neutrophils, and unchanged numbers of macrophages were reported after acute cigarette 
smoke exposure (Janoff et al., 1983; Morrison et al., 1999). On the other hand, it has been 
reported that BAL fluid from healthy chronic smokers contains only macrophages 
(Meuronen et al., 2008), or both macrophages and neutrophils (Kuschner et al., 1996). The 
difference in inflammatory cell types within the lung after cigarette smoke exposure is most 
likely related to the duration of exposure. Neutrophils tend to predominate in initial 
inflammatory reactions while macrophages predominate with time as inflammation 
continues. Thus, based on the fact that in this thesis the only cell type noted within the alveoli 
and BAL fluid after 14 and 28 day exposure was macrophages (see Figure 6.1), this pig ETS 
exposure model mimicked a longer-term exposure. It is possible that a neutrophilic 
inflammation (Figure 6.1) was present initially in this pig model, but that this was later 
replaced by macrophages. Future experiments examining earlier time points after daily ETS 
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exposure would be needed to better address this possibility versus a species-specific response 
unique to pigs. The inflammatory cells within the lung as well as epithelial cells contribute to 
oxidative stress by releasing free radicals (Sharafkhaneh et al., 2008). Smoking is also known 
to be a risk factor for the development of alveolar emphysema (Selman, 2003). Macrophages 
and neutrophils can release a number of elastolytic enzymes which can degrade the 
extracellular matrix such as MMP-9, MMP-12 and neutrophil elastase (Churg et al., 2008). 
Compared to healthy nonsmokers, the BAL fluid of healthy smokers contain higher levels of 
elastase activity (Janoff et al., 1983) which could eventually lead to dilated alveoli and overt 
emphysema. Thus, not only is elastase involved in COPD pathogenesis, but it is also 
indicative of a long period of inflammation. In this thesis, we found higher elastase activity 
in the BAL fluid from pigs exposed to cigarette smoke compared to sham exposed pigs but 
without histological evidence of emphysema. Thus, the duration of exposure in the pig ETS 
model used in this thesis appeared to be of a moderate length, consistent with a sub-chronic 
response. Overall, we believe that this inflammatory response within the lung is the key 
pulmonary response that is responsible for producing cardiovascular responses within the 
systemic circulation.  
Another key pulmonary response to ETS is the activation of Ahr by PAHs, which is 
known to play an important role in the generation of oxidative stress and in pulmonary 
carcinogenesis (Korashy and El-Kadi, 2006; Moorthy et al., 2003). The expression of 
CYP1A1 is considered a specific marker for Ahr activation.  Cytochrome P450 1A1 
metabolites such as quinones and epoxides are implicated in the generation of oxidative 
stress and in carcinogenesis, respectively (Levin et al., 1982). The finding of increased lung 
EROD activity after smoke exposure in this thesis is consistent with a critical role of PAHs 
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and Ahr in mediating oxidative stress within the lung via production of reactive metabolites 
that could be produced in sufficient quantities to exit the lung and exert systemic effects. 
However, the short half-life of these reactive metabolites makes this possibility less likely 
than alternative explanations. Instead, Ahr activation is more likely to play a direct role in 
regulating the inflammatory response within the lung. One study reported that the expression 
of IL-8 from alveolar macrophages increased after BAP exposure which could be reversed by 
the transfection of cells with silencing RNA against Ahr (Podechard et al., 2008).  
Additionally, it has been shown that Ahr activation results in increased expression of the 
chemokine CCL1 from alveolar macrophages (N'Diaye et al., 2006) and NF-B (Kobayashi 
et al., 2008), both of which would initiate pulmonary inflammatory responses. In this study, 
the increase in lung EROD activity was associated with histological evidence of 
inflammation i.e. macrophages. Based on the results of this thesis, we propose that Ahr 
activation by the PAH component of tobacco smoke within alveolar endothelial cells and in  
macrophages is responsible for initiating the inflammatory response that then spills over into 
the systemic circulation to cause adverse effects (Figure 6.1).  
 
6.4.  Proposed connection between pulmonary and systemic vasculature after tobacco 
smoke exposure 
Pulmonary endothelial cells show increased expression of adhesion molecules on their 
surface after tobacco smoke exposure (Scott and Palmer, 2003) and this serves to facilitate 
the recruitment of inflammatory cells to the lung. In addition to secreting chemokines, the 
inflammatory cells within lung as well as pulmonary parenchymal cells secrete cytokines that 
may have systemic effects. Macrophages and epithelial cells exposed to cigarette smoke 
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release IL-1β, TNF-α, and IL-6 which are known to increase the expression of adhesion 
molecules on the surface of endothelial cells (Scott and Palmer, 2003). Thus, although this 
was not measured in this thesis work, it is also possible that smoke particulates also 
contribute to increased expression of adhesion molecules on pulmonary vasculature (Figure 
6.1). Interestingly, it has been shown that the levels of neutrophil- and macrophage-attracting 
chemokines are elevated in guinea pig BAL fluid after single and repeated smoke exposure, 
while the levels of TNF-α are elevated after acute but not chronic exposure (Kubo et al., 
2005). Others also reported that repeated exposure results in an adaptive response within the 
lung characterized by lower levels of leukocytes within BAL fluid compared to acute 
exposure in pigs (Charavaryamath et al., 2005) . Unlike other studies which reported the 
presence of macrophages and neutrophils within BAL fluid and alveoli after chronic cigarette 
smoke exposure, the work in this thesis found only macrophages within alveoli and BAL 
fluid. Additionally, pulmonary capillaries were devoid of neutrophils and other leukocytes. It 
would be interesting to see if such an adaptive lung immune response occurs in the pig and 
whether the chemokine or cytokine levels within the lung and blood would change with more 
prolonged ETS exposures.  
Pulmonary endothelial cells may also become a source of oxidative stress. The exposure 
of human, bovine, and rat pulmonary endothelial cells to cigarette smoke extract resulted in 
superoxide anion production which could be reversed by the inhibition of NADPH oxidase 
(Jaimes et al., 2004). We found that brachial artery FMD was impaired after smoke 
exposure, which indicates that cigarette smoke has negative effects on the systemic 
vasculature. Tobacco smoke exposure results in systemic vascular effects by one of the 
following mechanisms. First, free radicals within tobacco smoke and tobacco smoke 
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constituents, especially, within the particulate phase, can reach the systemic circulation 
resulting in inflammation and oxidative stress within the vasculature. Second, the 
inflammatory response within the lung can also spillover into the systemic circulation and 
contribute to endothelial dysfunction. However, once again, the short half-life of superoxide 
free radicals makes the possibility of ROS effects outside the lung and the former possibility 
seem unlikely. Therefore, based on the results of this thesis, we propose that the latter 
possibility of inflammatory spillover is the connection between pulmonary ETS effects and 
cardiovascular effects (Figure 6.1). Tobacco smoke contains many compounds that can cross 
from the lung into the blood stream such as nitrogen oxides, isoprene, butadiene, benzene, 
styrene, formaldehyde, acetaldehyde, acrolein, furan, as well as many heavy metals like 
cadmium arsenic and lead. Many of these compounds can cause endothelial dysfunction. 
Increased systemic oxidative stress and inflammation have been implicated in the 
impairment of FMD through the inactivation of NO (Karatzi et al., 2007). In this thesis, we 
found that both ETS exposure and BAP injection resulted in systemic inflammation (high 
CRP levels), increased oxidative stress and increased biological inactivation of NO (high 
nitrotyrosine) which should have produced similar levels of impairment in endothelial 
function. However, FMD was impaired only after ETS exposure. Therefore, these results at 
first do not appear to support our proposed mechanism of action for pulmonary ETS 
exposure effects. However, another factor that must be considered is that FMD in pigs may 
not be entirely NO-dependent. We hypothesize that endothelium-derived hyperpolarizing 
factor (EDHF) may compensate in certain cases where NO bioavailability is impaired (Figure 
6.1). In support of this, EDHF has been shown to preserve endothelium-dependent dilation 
when NO-dependent mechanisms become impaired in animal models of congestive heart 
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failure (Ueda et al., 2005). Thus, the FMD response may have switched from an NO-
dependent to an EDHF-mediated dilation after BAP exposure; thereby maintaining the FMD 
response despite decreased NO bioavailability in the current thesis. However, why a similar 
compensation did not occur after ETS exposure in this thesis work is not clear. One 
explanation may be the difference in exposure time (7 days versus 28 days) which would 
mean that EDHF compensation for lack of NO-dependent dilation is transient. Therefore, the 
relative contribution of NO versus EDHF in the FMD response needs to be investigated more 
specifically in future time-course experiments with ETS and BAP. Alternatively, the absence 
of FMD impairment after intravenous BAP administration may indicate that the lung-induced 
inflammatory response has unique systemic effects. This is supported by the finding that 
nonsmoking COPD patients have impaired FMD and elevated levels of serum CRP (Pinto-
Plata et al., 2006). Additionally, in a study involving 39 patients who underwent lung 
resection, divided into three groups, nonsmokers, smokers with normal lung function and 
patients with COPD.  The pulmonary artery endothelial cells of COPD patients developed 
lower relaxation in response to ADP than nonsmokers and smokers (Peinado et al., 1999). 
An important inflammatory mediator which could be responsible for systemic effects is IL-6. 
Interleukin-6 has been shown to leak out from the lung to the systemic circulation after 
endotoxin exposure (Tamagawa et al., 2009). Furthermore, IL-6 is elevated in smokers and is 
known to drive the expression and release of CRP from the liver. Recently it has been shown 
that CRP induces endothelial dysfunction and uncoupling of eNOS in vivo (Hein et al., 
2009). It would be interesting to see if the lung is the primary source of IL-6 after ETS 
exposure. If so, it would solidify the primary role of lung induced inflammation we propose 
in cardiovascular disease from ETS.  
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Figure 6.1: Proposed sequence of events explaining how flow mediated dilation (FMD) 
could be impaired after environmental tobacco smoke exposure (ETS) exposure and a 
possible reason for lack of impairment after intravenous benzo[a]pyrene (BAP) 
administration. EDHF: endothelium-derived hyperpolarizing factor. Ahr: Aryl 
hydrocarbon receptor. NO: nitric oxide. eNOS: endothelial nitric oxide synthase. ROS: 
reactive oxygen species. CRP: C-reactive protein. IL-1: Interleukin-1. TNF- α: Tumor 
necrosis factor- α . IL-6: Interluken-6. EROD: ethoxyresorufin-o-deethylase. 
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6.5.  Deficiencies of studies in this thesis  
The use of oscillometery for blood pressure evaluation may have failed in detecting 
subtle differences in blood pressure. Telemetry is now considered the gold standard approach 
for blood pressure evaluation. However, this method is invasive, costly, requires trained 
personnel and is not a standard procedure in larger animals such as pigs, but would be a 
logical next step for future ETS experiments in this pig model. The use of larger sample 
numbers to examine all the above effects will also help strengthen our conclusion.  
  
6.6.  Future experiments 
The cause of FMD impairment was not established in this thesis. Therefore, future studies 
would focus on investigating the role of other vasodilators, such as EDHF in mediating 
FMD. This could be achieved by administering pharmacological blockers of EDHF, such as 
apamin and charybdotoxin, or a placebo to normal healthy pigs and monitoring FMD.  
Additionally, the role of inflammatory mediators in FMD impairment after ETS exposure 
should also be investigated. This could be done by measuring the levels of these mediators, 
such as IL-1, TNF- α and IL-6 in the systemic circulation and correlating their levels with 
eNOS expression, NO levels and FMD impairment after ETS exposure. It would be 
interesting to compare the difference in immune response in the lung after single and 
repeated exposures to ETS. This may shed some light on the adaptation process that may 
occur in the lung after repeated exposure. Finally, the beneficial cardiovascular effects of 
RES should be further examined using a wider range of doses, especially in whole animal 
models rather than in vitro.  
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6.7.  Significance of thesis work: Social and health significance of environmental tobacco 
smoke and resveratrol 
Cigarette smoking is known to impact the health of smokers affecting almost every organ 
system. Although there is increasing evidence linking exposure to ETS in non-smokers to 
several disease processes, the link is often controversial. The claim that ETS exposure has 
no, or at most, a minor health impact is based on ETS exposure being intermittent. Thus, the 
argument is that ETS yields only low and subclinical toxic exposures in non-smokers. 
However, almost all regulations govern smoking in public places and virtually no regulations 
govern cigarette smoking in private places. This claim does not take into consideration the 
repetitive nature of ETS exposure in private spaces such as the home, particularly when a 
family member smokes indoors. Additionally, the impact of ETS exposure on people with 
other pre-existing cardiovascular and pulmonary diseases is not clear, but is likely 
underestimated. Results from this thesis strongly indicate that people at risk of CVD develop 
a clinically measurable impairment in flow mediated dilation even after short, discontinuous 
exposures to ETS. Pigs provide a valuable model to study cardiovascular diseases as they are 
more similar to human beings in terms of diet, anatomy, aortic size and progression of CVD 
than rodents or dogs. The pigs used in the ETS exposure experiments were weaning age. 
Thus, such exposure mimics a scenario of a smoking parent causing negative health effects to 
his/her 1-2 year old children.  Since there are no laws governing smoking in private places 
such as the home, this represents a relevant and common exposure scenario. 
 
Dietary supplements are widely used because of their claimed health benefits. Unlike 
prescribed medications, which are known to have specific targets affecting a particular 
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disease pathway, the advertised health effects of dietary supplements are often more general 
and poorly defined. Claims of preventing or improving a wide variety of disease processes as 
well as increasing life span are common. Additionally, until recently, the manufacturing of 
dietary supplements was subject to limited oversight. Although the regulations and 
monitoring of manufacturing supplements have improved in recent years, critics still point 
out that less rigorous regulations for dietary supplements are implemented than those of drug 
counterparts.  Resveratrol is a natural food supplement found in the skin of red grapes as well 
as other food items. The advertised health benefits of RES were first focused on the 
cardiovascular system with studies linking its consumption to decreased incidence of several 
CVDs. In recent years, the claimed health benefits of RES have been expanded to include 
cancer prevention and treatment as well as increasing life span. While many studies have 
reported beneficial effects of RES in vitro, the in vivo effects are far from being clear at this 
stage with quite a few studies challenging its health benefits. The results from this thesis 
indicate that RES consumption is not protective for the CVD under the conditions assessed 
here.  
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